



**UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL  
FACULDADE DE MEDICINA  
PROGRAMA DE PÓS-GRADUAÇÃO EM PSIQUIATRIA E CIÊNCIAS DO  
COMPORTAMENTO**

*DISSERTAÇÃO DE MESTRADO*

**PREDITORES DE HETEROGENEIDADE COGNITIVA NO  
TRANSTORNO BIPOLAR: UMA ABORDAGEM *MACHINE-  
LEARNING***

**Francisco Diego Rabelo da Ponte**

**Orientador: Prof. Dr. Maurício Kunz**

**Porto Alegre**

**2018**

**UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL**  
**FACULDADE DE MEDICINA**  
**PROGRAMA DE PÓS-GRADUAÇÃO EM PSIQUIATRIA E CIÊNCIAS DO**  
**COMPORTAMENTO**

*DISSERTAÇÃO DE MESTRADO*

**PREDITORES DE HETEROGENEIDADE COGNITIVA NO**  
**TRANSTORNO BIPOLAR: UMA ABORDAGEM *MACHINE-***  
***LEARNING***

Dissertação apresentada à Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento como requisito parcial para a obtenção do título de Mestre em Psiquiatria e Ciências do Comportamento.

Autor: Francisco Diego Rabelo da Ponte

Orientador: Prof. Dr. Maurício Kunz

**Porto Alegre**

**2018**

CIP - Catalogação na Publicação

Rabelo da Ponte, Francisco Diego  
PREDITORES DE HETEROGENEIDADE COGNITIVA NO  
TRANSTORNO BIPOLAR: UMA ABORDAGEM MACHINE-LEARNING  
/ Francisco Diego Rabelo da Ponte. -- 2018.  
73 f.  
Orientador: Maurício Kunz.

Dissertação (Mestrado) -- Universidade Federal do  
Rio Grande do Sul, Faculdade de Medicina, Programa  
de Pós-Graduação em Ciências Médicas: Psiquiatria,  
Porto Alegre, BR-RS, 2018.

1. Neuropsicologia. 2. Transtorno Bipolar. 3.  
Machine Learning. 4. Cognição. 5. Inteligência  
Artificial. I. Kunz, Maurício, orient. II. Título.

**PREDITORES DE HETEROGENEIDADE COGNITIVA NO  
TRANSTORNO BIPOLAR: UMA ABORDAGEM *MACHINE-  
LEARNING***

Dissertação como requisito parcial para a obtenção do título de Mestre em Psiquiatria e Ciências do Comportamento, apresentada à Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento.

**Porto Alegre, 02 de março de 2018**

A Comissão Examinadora, abaixo assinada, aprova a Dissertação elaborada por Francisco Diego Rabelo da Ponte, como requisito parcial para a obtenção do Grau de Mestre em Psiquiatria e Ciências do Comportamento.

**Comissão Examinadora:**

---

**Prof.<sup>a</sup> Dr.<sup>a</sup> Juliana Fernandes Tramontina – Universidade Federal de Ciências da Saúde de Porto Alegre**

---

**Prof. Dr. Giovanni Abrahão Salum Júnior – Universidade Federal do Rio Grande do Sul**

---

**Prof. Dr. Ives Cavalcante Passos**

---

**Prof. Dr. Maurício Kunz – Universidade Federal do Rio Grande do Sul –  
Orientador**

## AGRADECIMENTOS

Às 242 pessoas do Brasil e da Espanha que se dispuseram a participar dessa pesquisa.

À Alexandra Elbakyan por seu hackativismo em criar o *Sci-Hub* e permitir que vários cientistas, principalmente os dos países subdesenvolvidos, tenham acesso à produção científica, rompendo com a lógica do capital das grandes editoras científicas.

Ao Prof. Maurício Kunz por acreditar nas minhas ideias, apoiá-las e me incentivar no percurso acadêmico. Sempre dando forças às minhas empreitadas!

À Prof.<sup>a</sup> Adriane Rosa por transmitir seu versátil conhecimento em neurociências e por me delegar suas “missões” que, na verdade, são autênticas charadas, acabam me incentivando a trilhar o caminho do desconhecido.

À Letícia Czepielewski por ser essa jovem pesquisadora que incentiva os pesquisadores mirins como eu. Meu muito obrigado pelos ensinamentos, pela paciência e por compartilhar comigo a crença em uma Ciência Psicológica forte e socialmente relevante.

Ao LabSof (Duda Dias, Gabi Berni, Luiza Géa, Thais Martini) por me acolherem desde o momento em que cheguei ao laboratório. Senti-me em casa durante um período bem difícil para mim. Demos muitas risadas e conselhos, reclamamos juntos, compartilhamos dores, emprestamos dinheiro uns aos outros. Muito obrigado pelo amor de vocês, gurias.

Ao PsicoLab (Flávia, Day, Mathias, Carol, Jô Bucker, Silvia, Raissa) por me acolherem e serem braço e cabeça da nossa pesquisa no PROTAHBI.

À Gi Bristot e Ellen Scotton pelas ideias de pesquisa e histórias da vida acadêmica compartilhadas!

À Jéssica Pessoa Gomes, amiga, amor, companheira, e acima de tudo minha irmã, por ser esse exemplo de perseverança, por estar ao meu lado mesmo com 5000 km de distância, por me apoiar nas minhas decisões. Obrigado, amiga, por me amar e nunca deixar que eu caísse sozinho. Te amo, *sister*!

Ao Iury Cavalcanti, meu melhor amigo. Quantas coisas nós já dividimos! Perdas, lutos, separações, mortes, cafés, doces, rapazes, sonhos, viagens. Obrigado por ser esse fiel e insistente amigo que me complementa. Sol e Lua. Te amo, amigo!

À Camila Ricarte por ser minha primeira amiga da faculdade! Obrigado por permanecer na minha vida. Você é uma pessoa que nutro um amor e afeto tremendamente especial. Te amo, mana!

À Juliana Cysne por ser comigo a melhor companhia e por dividir tua(s) história(s) comigo! Obrigado por todo apoio que me deu e me dá. Te amo, amiga. Logo nos encontraremos de novo.

Aos Seis Elementos por serem meus melhores amigos e estarem comigo por longas décadas desde a época da escola. Cada um de nós já passou por vários caminhos e os laços só se tornam mais robustos.

Às Princesas da Disney (Henrique, Vanessa, Tati, Manu, Mônica) por serem os melhores amigos! Amo vocês!

Por fim, aos meus pais que SEMPRE me incentivaram a percorrer os meus sonhos e a buscar conhecimento.

## LISTA DE ABREVIATURAS E SIGLAS

ANOVA – Análise de variância

BDNF - *Brain-derived neurotrophic factor*

CART - *Classification and Regression Tree*

CVLT - *California Verbal Learning Test*

DFA - Análise de Função Discriminante

DSM – Manual Estatístico e Diagnóstico de Transtornos Mentais

FAS -Fluência Verbal Fonológica

HAM-D-17- Escala de Avaliação de Depressão de Hamilton

HCA - Análise de Cluster Hierárquica

HCPA - Hospital de Clínicas de Porto Alegre

HVLT-R Hopkins Verbal Learning Test – Revised

MANOVA – Análise multivariada de variância

PROTAHBI - Programa de Transtorno de Humor Bipolar

SCID-4-CV- Entrevista Clínica Estruturada para os Transtornos do DSM-4 – Versão Clínica

SNL - Sequência de Números e Letras

SWCT - Stroop Word Color Test

TB – Transtorno Bipolar

TMT-A - Trail Making Test -A

TMT-B- Trail Making Test-B

YMRS - Young Mania Rating Scale

WAIS-III - Escala de Inteligência Wechsler para Adultos – 3ª Edição

## RESUMO

*Objetivos:* Identificar os preditores de heterogeneidade cognitiva nos sujeitos com Transtorno Bipolar (TB). *Métodos:* Foi recrutado 142 sujeitos com TB em atendimento ambulatorial e 100 voluntários sem transtornos psiquiátricos do Brasil e da Espanha para realizar avaliação neuropsicológica. Foi realizado Análise de *Cluster* Hierárquica e Análise de Função Discriminante para determinar e confirmar os subgrupos cognitivos. Por fim, foi usado o algoritmo *Classification and Regression Tree* (CART) para identificar os preditores dos subgrupos cognitivos anteriormente estabelecidos. *Resultados:* Foi observado a presença de três *clusters* cognitivos: indivíduos cognitivamente intacto (38%), seletivamente prejudicados (38%) e globalmente prejudicados (21%). Os preditores mais importantes foram anos de educação, anos de doença, número de hospitalizações, idade e idade de início. *Conclusão:* Os resultados corroboram com recentes achados sobre a heterogeneidade cognitiva nos sujeitos com TB. Além disso, os presentes achados indicam uma sobreposição entre aspectos neurodesenvolvimentais e história de doença.

Palavras-chave: Transtorno Bipolar, heterogeneidade cognitivo, análise de cluster, árvore de decisão.



## **ABSTRACT**

*Objective:* We aimed to determine predictors of cognitive heterogeneity in subjects with Bipolar Disorder (BD).

*Methods:* We recruited 142 outpatients with Bipolar Disorder and 100 unaffected volunteers from Brazil and Spain that underwent a neuropsychological assessment. We performed Hierarchical Cluster Analysis and Discriminant Function Analysis to identify and validate cognitive subgroups, respectively. Then, we used Classification and Regression Tree (CART) algorithm to determine predictors of the cognitive clusters.

*Results:* We identified three cognitive clusters in BD: intact (38%), selectively impaired (38%), and globally impaired subjects (21%). The most important predictors of cognitive subgroups were years of education, years of disease, the number of hospitalizations, age, and age of onset, respectively.

*Conclusion:* These results corroborate with recent findings of neuropsychological heterogeneity in Bipolar Disorder. Furthermore, the present findings suggest overlapping between neurodevelopmental and morbid aspects.

*Key words:* Bipolar Disorder, cognitive heterogeneity, cluster analysis, decision tree.

## SUMÁRIO

<b>1 Apresentação.....</b>	<b>11</b>
<b>2 Introdução.....</b>	<b>12</b>
2.1 Neurodesenvolvimento cognitivo no Transtorno Bipolar.....	12
2.2 Neuroprogressão.....	14
2.3 Heterogeneidade cognitiva.....	16
2.4 <i>Machine learning</i> .....	17
<b>3 Justificativa.....</b>	<b>18</b>
<b>4 Objetivos.....</b>	<b>19</b>
4.1 Objetivos gerais.....	19
4.2 Objetivos específicos.....	19
<b>5 Método.....</b>	<b>19</b>
5.1 Critérios de inclusão.....	19
5.2 Critérios de exclusão.....	20
5.3 Instrumentos e medidas.....	20
5.3.1 Entrevista clínica e escalas de sintomatologia e diagnóstico.....	20
5.3.2 Avaliação neuropsicológica.....	20
5.4 Procedimento.....	21
5.5 Análise estatística.....	22
<b>6 Resultados.....</b>	<b>23</b>
6.1 Artigo 1: Predictors of cognitive heterogeneity in a transcultural sample of individuals with Bipolar Disorder: a machine-learning approach.....	23
<b>7 Aspectos éticos.....</b>	<b>52</b>
<b>8 Considerações finais.....</b>	<b>52</b>

## 1. Apresentação

O Transtorno Bipolar (TB) é um transtorno psiquiátrico crônico e grave, cuja prevalência é de aproximadamente 1% da população(1). Além disso, é considerado uma das dez doenças mais incapacitantes no mundo(1). É um transtorno com altas taxas de suicídio. Aproximadamente, 7,8% dos homens e 4,9% das mulheres com TB cometem suicídio(2,3). Seus sintomas são caracterizados pela presença de episódios maníacos ou hipomaníacos e depressivos, intercalados por intervalos eutímicos(4). Os sujeitos acometidos pelo TB apresentam um marcante prejuízo funcional mesmo em períodos assintomáticos. Assim, pacientes com esse transtorno comumente possuem dificuldades no trabalho, em executar as atividades de vida diária, nos relacionamentos interpessoais e em outros domínios psicossociais (5).

Os déficits cognitivos e sintomas subsindrômicos são importantes preditores de prejuízos funcionais (6). Essa população tem 4 a 10 vezes mais disfuncionalidade que a população geral (7,8). As alterações cognitivas presentes no TB são independentes do estado do humor, persistindo mesmo em períodos eutímicos para a maioria dos pacientes. Os principais domínios cognitivos prejudicados são memória verbal, função executiva, velocidade de processamento e atenção sustentada (8).

A presente dissertação consiste em um estudo multicêntrico transversal envolvendo avaliação cognitiva de pacientes com TB e utilizando algoritmos de *machine learning* para analisar os dados. O artigo resultante dessa pesquisa foi submetido no JAMA Psychiatry com o título “Predictors of cognitive heterogeneity in a transcultural sample of individuals with Bipolar Disorder”.

## **2. Introdução**

### **2.1 Neurodesenvolvimento cognitivo no Transtorno Bipolar**

O desenvolvimento cognitivo dos pacientes com TB ocorre de maneira particular ao longo da vida. No período pré-mórbido, a cognição se desenvolve de maneira ascendente similar a de um indivíduo sem histórico de transtorno psiquiátrico. Em alguns casos, esses sujeitos apresentam um desenvolvimento cognitivo acima da média da população infanto-juvenil (9). Entretanto, esse cenário muda a partir do primeiro episódio de humor, modificando a trajetória do desenvolvimento cognitivo. Dessa forma, os déficits na cognição já se tornam visíveis desde esse momento (4). A cada episódio de humor aumenta a severidade do prejuízo cognitivo, tornando-se progressivo e persistente mesmo em fases eufímicas. Além disso, múltiplos episódios aumentam a vulnerabilidade a episódios subsequentes e reduzem a resposta ao tratamento (10,11). Dessa maneira, os pacientes em estágios avançados do TB apresentam severos déficits cognitivos similares aos pacientes com esquizofrenia (12).

Entretanto, um subgrupo de pacientes apresenta um atraso no desenvolvimento cognitivo antes do primeiro episódio de humor, exibindo padrão semelhante aos pacientes com esquizofrenia. Algumas teorias neurodesenvolvimentais afirmam que determinados fatores de risco podem levar a um atípico desenvolvimento cerebral e, conseqüentemente, uma dificuldade na aquisição de habilidades cognitivas (9). Um recente estudo aponta que possivelmente esse subgrupo de pacientes compartilha genes em comum com a esquizofrenia (13). Outro estudo tem evidenciado que o déficit cognitivo pré-mórbido no TB pode estar associado com genes responsáveis pela maturação cerebral (14). Além disso, insultos pré-natais como influenza gestacional

pode aumentar em quatro vezes o risco de desenvolver TB na vida adulta (15). Em um estudo longitudinal com crianças em idade escolar, acharam uma associação entre baixo rendimento acadêmico e o risco de desenvolver TB (16). Nessa mesma direção, crianças de mães com TB ou esquizofrenia apresentam três vezes mais chances de terem deficiência intelectual (17). Deste modo, distintos cursos neurodesenvolvimentais podem estar relacionados com a heterogeneidade cognitiva entre os pacientes com TB após início da doença.

Outros eventos durante o curso de vida podem aumentar a gravidade da doença. Dentre eles, o trauma precoce é um importante fator pré-mórbido no TB, uma vez que há altas taxas de pacientes com TB que sofreram trauma infantil (18). A exposição à estressores na infância está associado a uma idade de início precoce do transtorno, presença de comorbidade com Transtorno de Estresse Pós-Traumático, ciclagem rápida, sintomas ansiosos, maior número de tentativas de suicídio e maior quantidade de episódios de humor (19,20). O TB parece ser um transtorno sensível ao estresse com o primeiro episódio sendo, frequentemente, engatilhado por eventos estressores ambientais (21). Cognitivamente, o trauma precoce está relacionado a um pior desempenho em funções como controle inibitório, atenção, memória verbal e de trabalho (22,23).

Além do trauma precoce, outro aspecto pré-mórbido relacionado a desfechos cognitivos é a reserva cognitiva. Reserva cognitiva é a capacidade do cérebro de sustentar as atividades cognitivas e enfrentar processos patológicos cerebrais (24). Os anos de estudo são um importante *proxy* de reserva cognitiva (25). Diferentes níveis de reserva cognitiva podem levar a múltiplos desfechos após um insulto cerebral (26). Distintas características de reserva cognitiva podem influenciar o prejuízo cognitivo em vários transtornos psiquiátricos como no TB. Foi visto que pacientes com TB com alta

reserva cognitiva apresentam melhores desempenhos em testes neuropsicológicos e melhor funcionamento psicossocial (25). Dessa forma, a reserva cognitiva é um significativo preditor de funcionamento cognitivo e psicossocial em pacientes eutímicos, exercendo um papel modulador em diferentes trajetórias cognitivas no TB (24,27).

## **2.2 Neuroprogressão**

Há evidências que os pacientes com TB apresentam um declínio nas habilidades cognitivas associado ao número de hospitalizações e ao número de episódios de humor (28). Essa deterioração ao longo do curso do TB é chamada de neuroprogressão, ou seja, com os anos de doença e o número de episódios de humor, os pacientes começam a apresentar uma deterioração cognitiva e funcional, refratariedade ao tratamento, vulnerabilidade ao estresse e atrofia cerebral (29,30). Pacientes em estágios tardios da doença com mais de dez episódios maníacos e, ao menos, com uma hospitalização exibiram um pior desempenho em testes de memória verbal que pacientes em estágios iniciais e pessoas sem transtornos psiquiátricos (31,32). Uma recente metanálise apontou que o número de episódios maníacos afetava memória verbal e função executiva, enquanto o número de episódios depressivos não apresentou essa associação (33). Há outros dados evidenciando que o número de episódios, anos de doença, número de hospitalizações, idade de início da doença são marcadores de gravidade relacionados a uma piora em habilidades cognitivas como velocidade psicomotora, flexibilidade cognitiva, função executiva, memória verbal e atenção (28).

Além dos aspectos cognitivos, a progressão da doença também está associada aos desfechos clínicos mais desfavoráveis como elevadas taxas de comorbidades clínicas, pior disfuncionalidade, menor intervalo inter-episódios, aumento de risco de

suicídio e de hospitalização(34). Pacientes em estágios mais tardios do transtorno têm uma pior resposta ao lítio, à terapia cognitivo-comportamental e à psicoeducação de seus cuidadores(35–37). Outros medicamentos como olanzapina e lamotrigina só melhoraram os sintomas daqueles pacientes com poucos episódios de humor e poucas hospitalizações (38,39). Um estudo transversal mostrou que, no estágio I, era mais frequente monoterapia, no estágio II, a combinação de duas drogas e, nos estágios tardios, era necessário o uso de três ou mais medicações ou clozapina. Ademais, havia uma correlação positiva entre funcionamento psicossocial e uso de medicações psicotrópicas (40).

Ativação imune e falhas nos mecanismos compensatórios podem ser mecanismos relacionados à fisiopatologia da neuroprogressão no TB. Pacientes em estágios tardios tem menores níveis de fator neurotrófico derivado do cérebro (*Brain-derived neurotrophic factor* - BDNF), citocinas anti-inflamatórias, maiores níveis de substratos do estresse oxidativo e citocinas pró-inflamatórias que pacientes em estágios iniciais (34,41). Em estudos *post-mortem*, tem mostrado que pacientes com TB têm alterações no número, tamanho e densidade de neurônios em regiões corticais e subcorticais (42). Um estudo recente utilizando *machine-learning* identificou que os pacientes com TB tinham maiores níveis de eotaxin-1 (CCL11) e glutathione S-transferase que indivíduos sem transtornos mentais. Porém, o algoritmo não conseguiu diferenciar os pacientes com TB e esquizofrenia em relação a esses biomarcadores periféricos, sugerindo que esses transtornos compartilham de fisiopatologias semelhantes(43).

### **2.3 Heterogeneidade cognitiva**

Os pacientes com TB não são homogêneos em relação ao prejuízo cognitivo. Apenas um terço dos pacientes apresenta disfunção cognitiva durante os períodos eutímicos (44). Essa variabilidade cognitiva pode refletir as diferentes etiologias do transtorno, a gravidade dos sintomas, os fatores de suscetibilidade genética e outros aspectos pré-mórbidos (45). Alguns autores sugerem que apenas um subgrupo de pacientes com TB apresenta um curso progressivo da doença associado aos fatores clínicos da doença(46).

Anteriormente, os pacientes eram agrupados em grupos cognitivamente prejudicados e não-prejudicados determinados por pontos de corte arbitrários. Em geral, esses pontos de corte eram baseados na amostra de sujeitos sem transtornos psiquiátricos em que um desvio-padrão abaixo de 0,5 a 1,5 era considerado prejuízo cognitivo (47). O problema desse tipo de estratificação binária é a perda de especificidades que possam existir dentro dessas sub-amostras (47). A partir disso, tem crescido o número de estudos que tem utilizado algoritmos de *machine-learning* para identificar subgrupos cognitivos. Esses métodos utilizam algoritmos (p.ex. *k-NN* ou *k-means algorithm*) para identificar automaticamente similaridades e diferenças dentro de um grupo e dividi-lo em subgrupos baseados na homogeneidade intra-grupo e/ou heterogeneidade entre-grupos (48).

Dessa maneira, várias pesquisas têm usado esses algoritmos para classificação cognitiva dos pacientes com TB. Em geral, apontam para a existência de três subgrupos (*clusters*) cognitivos: I) cognitivamente intacto; II) seletivamente prejudicado; III) globalmente prejudicado. O primeiro *cluster* apresenta um funcionamento neuropsicológico similar ao dos indivíduos sem transtornos psiquiátricos, sendo 30 a 46% dos pacientes. Já o segundo *cluster* possui um prejuízo cognitivo moderado a grave em dois ou três domínios cognitivos similar ao grupo globalmente prejudicado. Porém,



em outras funções cognitivas, possuem funcionamento semelhante ao *cluster* intacto. As funções cognitivas afetadas no *cluster* seletivamente prejudicado variam dependendo do estudo. Por fim, o grupo globalmente prejudicado apresenta um grave comprometimento cognitivo em todos os domínios com desvio-padrão bem abaixo de 1,5 (i.e. memória de trabalho, memória verbal, velocidade de processamento, controle inibitório, fluência verbal) (8,24,49).

Um recente estudo utilizando análise de classe latente identificou quatro subgrupos cognitivos: um com bom desempenho cognitivo, outro severamente prejudicado e outros dois com prejuízo moderado no controle inibitório e na resolução de problemas(45). Nessa mesma linha, outros autores acharam também quatro *clusters* cognitivos. Um subgrupo com prejuízo global, outro com funcionamento cognitivo normal e os outros dois com desempenho neuropsicológico próximo do normal. Porém, esses dois subgrupos diferiam apenas na memória verbal, pois um possuía prejuízo nesse domínio, enquanto o outro *cluster* teve um desempenho acima da média nessa função cognitiva (50).

De maneira geral, tem se replicado os achados a respeito da existência de um subgrupo com funcionamento cognitivo intacto e outro subgrupo com um funcionamento cognitivo globalmente prejudicado. No meio desses dois *clusters*, há a presença de outro subgrupo que apresenta uma performance cognitiva prejudicada em alguns domínios.

## **2.4 Machine learning**

*Machine learning* é um campo da Inteligência Artificial que detecta automaticamente padrões em uma base de dados por meio de alguns tipos de aprendizado. É necessários seguir alguns passos para a aplicação de qualquer algoritmo

de *machine learning*. O primeiro passo é a coleta dos dados. O segundo é preparação e exploração dos dados. Nessa etapa é preciso eliminar ou corrigir qualquer dado que seja desnecessário para a performance da máquina. O terceiro passo é o treino do modelo em que será aplicado o algoritmo. Assim, a máquina irá reconhecer um padrão no banco de dados de treino e o algoritmo representará o dado em forma de modelo. O passo seguinte consiste em avaliar o modelo. Dessa maneira, será avaliado quão bem o algoritmo aprendeu a partir da sua experiência com um banco de dados(48).

O aprendizado em *machine learning* é classificado em duas categorias: aprendizado supervisionado e não supervisionado. O primeiro utiliza a experiência de um banco de treino para ganhar perícia ao analisar um banco de teste. Em outras palavras, é mostrado à máquina exemplos rotulados de *input* e *output* em um banco de treino. Dessa forma, a máquina, em um banco de teste, verificará o que aprendeu, ou seja, é um processo em que o algoritmo aprende por meio de uma instrução (48,51).

O aprendizado não supervisionado é usado em dados sem rótulos anteriores e o algoritmo deve identificar um padrão nas variáveis apresentadas. Não há distinção entre o banco de treino e teste como é no aprendizado supervisionado. Além disso, Uma tarefa clássica de aprendizado não-supervisionado é análise de *cluster*, pois agrupa objetos de acordo com a sua similaridade sem a necessidade de um treino ou de um rótulo para predizer os grupos (52).

### **3. Justificativa**

Apesar dos avanços na compreensão dos aspectos cognitivos do TB, poucos estudos têm investigado a cognição nos subgrupos nessa população psiquiátrica e nenhum estudo investigou a relação de fatores pré-mórbidos e mórbidos relacionados a esses desfechos cognitivos. Esse tipo de pesquisa é importante para compreender a

complexidade do transtorno e entender as diferentes trajetórias da doença. Portanto, torna-se necessário investigar a heterogeneidade neuropsicológica dessa população e pesquisar os fatores associados às diferentes trajetórias no TB.

#### **4. Objetivos**

##### **4.1 Objetivos gerais**

Investigar o impacto dos fatores pré-mórbidos e mórbidos na cognição de Pacientes com TB.

##### **4.2 Objetivos específicos**

- Identificar quais são os *clusters* cognitivos existentes no TB;
- Investigar o impacto da reserva cognitiva dos pacientes com TB nos domínios cognitivos;
- Determinar quais aspectos mórbidos influenciam nos desfechos cognitivos.

#### **5. Método**

##### **5.1 Critérios de inclusão**

Os critérios de inclusão para os pacientes foram: homens e mulheres entre 18 e 65 anos, diagnóstico de Transtorno Bipolar Tipo I ou II pelo DSM-IV, pacientes eutímicos por, no mínimo, dois meses antes da avaliação com pontuação na *Young Mania Rating Scale* (YMRS) e *Hamilton Depression Rating Scale* (HAM-D-17) menor ou igual a sete, capacidade para entender e concordar com todos os aspectos do Termo de Consentimento Livre Esclarecido.

Os critérios de inclusão para os sujeitos sem transtornos psiquiátricos foram: homens e mulheres entre 18 e 65 anos, sem uso de medicação psiquiátrica e sem

história prévia de transtornos psiquiátricos, capacidade para entender e concordar com todos os aspectos do Termo de Consentimento Livre Esclarecido.

## **5.2 Critérios de exclusão**

Os critérios de exclusão para os pacientes foram diagnóstico de deficiência intelectual, grave comorbidade médica, presença de demências, analfabetismo, eletroconvulsoterapia no último ano e abuso de substância.

Os critérios de exclusão para os sujeitos sem transtornos psiquiátricos foram histórico atual ou passado de transtorno psiquiátrico ou doença neurológica, analfabetismo, presença de familiar de primeiro grau com transtorno psiquiátrico ou doença neurológica.

## **5.3 Instrumentos e medidas**

### **5.3.1 Entrevista clínica e escalas de sintomatologia e diagnóstico**

- Entrevista Clínica Estruturada para os Transtornos do DSM-4 – Versão Clínica (SCID-4-CV)(53).
- Escala de Avaliação de Mania de Young (YMRS) (54).
- Escala de Avaliação de Depressão de Hamilton (HAM-D-17) (55).
- Entrevista estruturada para a coleta dos dados sócio-demográficos e características clínicas do paciente;

### **5.3.2 Avaliação neuropsicológica**

- *Hopkins Verbal Learning Test – Revised*(56);
- *California Verbal Learning Test (CVLT)*(57);
- O subteste Sequência de Números e Letras da Escala de Inteligência Wechsler para Adultos – 3ª Edição (WAIS-III)(58);

- *Trail Making Test -A e Trail Making Test-B*(59);
- *Stroop Word Color Test*(60);
- Fluência Verbal Fonológica (FAS) (61).

**Tabela 1. Instrumentos que serão utilizados e as funções avaliadas**

<b>Instrumentos</b>	<b>Função avaliada</b>
Escala de Avaliação de Mania de Young (YMRS)	Sintomas Maníacos
Escala de Avaliação de Depressão de Hamilton (HAM-D-17)	Sintomas depressivos
<i>Hopkins Verbal Learning Test – Revised</i>	Memória verbal
<i>California Verbal Learning Test</i>	
Sequência de Números e Letras (WASI-III)	Memória de trabalho
<i>Trail Making Test –A</i>	Velocidade de processamento
<i>Trail Making Test-B</i>	Flexibilidade cognitiva
<i>Stroop Word Color Test</i>	Controle inibitório
Fluência Verbal Fonológica (FAS)	Fluência verbal

#### **5.4 Procedimento**

A amostra de pessoas sem transtornos psiquiátricos foi recrutada, por conveniência, de dois hospitais universitários do Brasil e da Espanha. A amostra foi de 242 participantes. 142 pessoas com diagnóstico de TB e 100 indivíduos sem transtornos psiquiátricos. Do Brasil, foram 59 voluntários saudáveis e 72 pacientes. Da Espanha, foram 41 indivíduos saudáveis e 70 pacientes com TB. A amostra de pacientes foi recrutada do Programa de Transtorno Bipolar dos mesmos hospitais universitários. O diagnóstico foi dado por experientes psiquiatras de acordo com Entrevista Clínica

Estruturada para os Transtornos do DSM-IV – Versão Clínica (SCID-4-CV). Os testes neuropsicológicos e as escalas psicométricas foram aplicados por experientes psicólogos. As avaliações foram realizadas individualmente, em um ambiente climatizado e sem ruídos de acordo com as diretrizes para o uso de testes da Comissão Internacional de Testes. Dados sobre variáveis sociodemográficas e clínicas foram coletadas para este protocolo.

### **5.5 Análise estatística**

O programa estatístico utilizado foi R *software* versão 3.4.2 para *Windows* para analisar os dados (<https://www.Rproject.org/>). Teste qui-quadrado e ANOVA foram realizados para verificar as diferenças entre os grupos das variáveis demográficas, considerando um nível de significância  $p < 0,05$ .

Para identificar a presença de subgrupos cognitivos em nossa amostra foi realizado alguns passos. As variáveis neuropsicológicas dos pacientes foram convertidas em *z-score* baseadas na média e desvio-padrão da amostra de controles correspondente de cada país. A conversão dos valores brutos em *z-score* foi feita para que todas as variáveis fossem comparáveis entre si. Em seguida, foi realizada uma Análise de *Cluster* Hierárquico (HCA) com o método de Ward e distância euclidiana ao quadrado com todos os domínios cognitivos avaliados para identificar os membros de cada *cluster* e o número de *clusters*.

Na próxima etapa, foi usado a Análise de Função Discriminante (DFA) para examinar a distância entre os centroides dos *clusters* e o poder preditivo da classificação da HCA. Por fim, realizaremos uma análise multivariada de variância (MANOVA) com a média dos *z-score* dos subgrupos para cada domínio cognitivo.

Após a identificação do número ideal de *cluster* e os seus membros, foi utilizado o algoritmo *Classification and Regression Tree* (CART) para realizar a árvore de

decisão. O objetivo desse tipo de análise é identificar quais são as variáveis pré-mórbidas e mórbidas que poderiam predizer cada *cluster* cognitivo. O *root node* foi os *clusters* cognitivos e, a partir disso, o algoritmo selecionou as variáveis de maior “peso” e realiza a divisão até que os *nodes* finais sejam homogêneos.

## 6. RESULTADOS

### 6.1 Artigo 1:

#### Carta de submissão no JAMA Psychiatry

February 20, 2018

Dear Dr Kunz:

Thank you for submitting your manuscript, "Predictors of cognitive heterogeneity in a transcultural sample of individuals with Bipolar Disorder," received on February 20, 2018, to JAMA Psychiatry. Your manuscript has been assigned the following manuscript number: PSY18-0263. Please refer to the manuscript number and corresponding author in all subsequent communications.

You may check the status of this manuscript by selecting the Check Manuscript Status link on the following Web page: <https://manuscripts.jamapsych.com/cgi-bin/main.plex?el=A4m7GrY7A3XaR4F5A9ftdvxeBdfYrdED7hyGyEfQZ>

Do not share this encrypted link with others, as it will automatically log you into your account for JAMA Psychiatry's Web-based system.

\* We agree to consider your manuscript with the understanding that its content, figures, and tables have not been published or submitted elsewhere in print or electronic format and will not be submitted elsewhere during the period of review by JAMA Psychiatry.

\* If you have not already done so, please provide copies of any manuscripts on closely related topics or with possibly duplicative material that have been previously published or are under consideration for publication elsewhere.

\* The information in your manuscript should not be distributed or released in hard copy or electronic form, except through presentation at scientific meetings, unless and until the manuscript is published.

\* The fact that your manuscript is under consideration by JAMA Psychiatry is confidential and should not be disclosed to anyone except coauthors and contributors.

Every effort will be made to expedite the review of your manuscript and to notify you of our decision as soon as possible. If you have questions or concerns, please contact the editorial office at [jamapsych@jamanetwork.org](mailto:jamapsych@jamanetwork.org) or +615-669-7181.

Thank you for the opportunity to consider your work.

Sincerely yours,

Dost Ongur, MD

Editor

JAMA Psychiatry

[jamapsych@jamanetwork.org](mailto:jamapsych@jamanetwork.org)

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.



## **Predictors of cognitive heterogeneity in a transcultural sample of individuals with Bipolar Disorder: a machine-learning approach.**

Francisco Diego Rabelo da Ponte<sup>1</sup>, Leticia Sanguinetti Czepielewski<sup>1</sup>, Flavia Moreira Lima<sup>1</sup>, Anabel Martinez-Aran<sup>2</sup>, Flávio Kapczinski<sup>3</sup>, Eduard Vieta<sup>2</sup>, Adriane Ribeiro Rosa<sup>1,4</sup>, Maurício Kunz<sup>1</sup>.

1. Molecular Psychiatry Laboratory, Hospital de Clinicas de Porto Alegre, Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
2. Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
3. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
4. Departamento de Farmacologia, UFRGS, Porto Alegre, Brazil. Programa de Pós-Graduação em Farmacologia e Terapêutica, UFRGS, Porto Alegre, RS, Brazil.

### **Corresponding author:**

Maurício Kunz

Department of Psychiatry

Universidade Federal do Rio Grande do Sul, Porto Alegre – RS, Brasil.

Phone: +55 51 33598021

E-mail: [maukunz@gmail.com](mailto:maukunz@gmail.com)

### **Email for all authors:**

Francisco Diego Rabelo da Ponte: [diegorabelop@gmail.com](mailto:diegorabelop@gmail.com)

Leticia Sanguinetti Czepielewski: [czepielewski@gmail.com](mailto:czepielewski@gmail.com)

Flavia Moreira Lima: [flamolima@gmail.com](mailto:flamolima@gmail.com)

Anabel Martinez-Aran: [amartiar@clinic.cat](mailto:amartiar@clinic.cat)

Flávio Kapczinski: [kapczinf@mcmaster.ca](mailto:kapczinf@mcmaster.ca)

Eduard Vieta: [evita@clinic.cat](mailto:evita@clinic.cat)

Adriane Ribeiro Rosa: [adrianerrosa@gmail.com](mailto:adrianerrosa@gmail.com)

Maurício Kunz: [maukunz@gmail.com](mailto:maukunz@gmail.com)

## **KEY POINTS**

*Question:* What are the clinical predictive factors of cognitive heterogeneity in subjects with Bipolar Disorder?

*Findings:* In this cross-sectional study involving 142 subjects with Bipolar Disorder and 100 unaffected subjects, there were three cognitive subgroups in individuals with Bipolar Disorder: intact (38%), selectively impaired (38%), and globally impaired individuals (21%). The most important predictors of cognitive subgroups were years of education, years of disease, the number of hospitalizations, age, and age of onset, respectively.

*Meaning:* Bipolar Disorder is a cognitively heterogeneous disease with an overlapping between premorbid and morbid factors, influencing multiple cognitive courses.

## **ABSTRACT**

*Importance:* Bipolar Disorder (BD) is an illness with heterogeneous outcomes, with a subset of patients exhibiting a progressive cognitive decline over the course of the disease. Early detection of neuropsychological subgroups is an important challenge in BD treatment and may help the clinical decision-making.

*Objective:* We aimed to identify predictors of cognitive clusters in individuals with Bipolar Disorder.

*Design, Setting, and Participants:* This is a multicenter cross-sectional study with a convenience sample. We recruited 142 outpatients with Bipolar Disorder and 100 unaffected volunteers from Brazil and Spain that underwent a neuropsychological assessment.

*Main Outcomes and Measures:* Of 142 participants with BD, 92 (64.9%) were female, and the mean (SD) age was 45.30 (12.24) years. Among 100 healthy volunteers, 63

(63%) were female, and the mean (SD) age was 42 (14.72) years. Individuals with BD were older compared to unaffected subjects ( $p < 0.001$ ). Cognitive tests used were Stroop Color and Word Test (inhibitory control), Trail Making Test A (processing speed), Trail Making Test B (cognitive flexibility), Verbal Fluency Test with letters F-A-S (verbal fluency), Letter-Number Sequencing from WAIS-III (working memory), Hopkins Verbal Learning Test–Revised trials 1-3 or California Verbal Learning Test trials 1-5 (short-term verbal memory), HVLT-R delayed recall trial or CVLT delayed recall trial (long-term verbal memory). We performed Hierarchical Cluster Analysis and Discriminant Function Analysis to determine and confirm cognitive clusters, respectively. Then, we used Classification and Regression Tree algorithm to determine predictors of the previously defined cognitive clusters.

*Results:* We identified three cognitive clusters in subjects with Bipolar Disorder: intact (38%), selectively impaired (38%), and globally impaired individuals (21%). The most important predictors of cognitive subgroups were years of education, years of disease, the number of hospitalizations, age, and age of onset, respectively.

*Conclusion and Relevance:* These results corroborate with recent findings of neuropsychological heterogeneity in Bipolar Disorder. Furthermore, the present findings suggest overlapping between premorbid and morbid aspects, influencing distinct courses of the disease.

*Key words:* Bipolar Disorder, cognitive heterogeneity, cluster analysis, decision tree, machine learning.

## 1. INTRODUCTION

Bipolar Disorder (BD) is a complex disease due to its clinical and cognitive heterogeneity. Cognitive deficits in euthymic patients with BD vary between 30 to 62% (62,63). The individuals with BD show dysfunctions in a wide range of cognitive domains as processing speed, memory, and executive functions(64). Furthermore, only one-third of patients after first-episode mania recover their psychosocial functioning similar to baseline(65). Previously, patients with BD were grouped into subjects with impaired and preserved cognitive function using arbitrary cut-off scores. The issue with this dichotomous classification is a lack of specificity that could be present at the sample. For this reason, data-driven approach such as cluster analysis is a method better than the ones to classify cognitive subgroups. Recently, several reports have suggested that there are three neuropsychological subgroups: a first group of patients with cognitive functioning similar to unaffected individuals (32%-48% of BD patients); a second group of patients who exhibited cognitive impairment in some cognitive functions, such as processing speed and attention (29%-40% of BD patients); and a third group of patients with severe cognitive impairment in several domains (12%-40% of BD patients)(8,66). These clusters showed similar intensity of mood symptoms but presented different degrees of psychosocial functioning, stress and quality of life(8,67).

The cognitive profiles in BD may be due to distinct trajectories of the disease, such as the influence of premorbid factors. For example, patients with high Cognitive Reserve (CR) displayed better cognitive performance than patients with low CR(24,25). CR refers to brain capacity of maintaining cognitive functions and coping pathological processes(24). Other premorbid features like childhood trauma and family history of psychiatric disorders may have different effects on the disease development. Furthermore, morbid factors such as number of hospitalizations, number of mood

episodes, and early onset of disease are also related to worse clinical, functional and cognitive outcomes(68,69). However, although there seems to be a subset of patients that exhibit a progressive cognitive decline over the course of the disease(70). BD is a highly variable illness that not necessarily will lead to unfavorable clinical outcomes.

Moreover, little is known about the possible predictors of the different cognitive profiles in BD, which could greatly improve our comprehension about the mechanisms of the illness progression. Clinically, early detection of neuropsychological subgroups is an important challenge in BD treatment. Therefore, our aim was to identify predictive factors of cognitive clusters in BD patients using Classification and Regression Tree (CART) algorithm. CART is a flexible machine-learning method widely used for diagnosis and classification of high-risk behaviors(71–74). This technique is able to identify complex nonlinear relations with interactive models(75,76). In other words, the algorithm automatically selects relevant features and determines cut points according to characteristics of data. These cut-points may be clinically relevant, indicating distinct clinical courses and helping the clinical decision-making.

## **2. METHODS**

### *2.1 Participants*

The sample included 242 participants, 142 individuals with BD and 100 healthy controls (HC). Participants were 59 healthy volunteers and 72 outpatients from the Bipolar Disorder Program at Hospital de Clínicas de Porto Alegre (HCPA) - Brazil, and 41 unaffected individuals and 70 outpatients from the Barcelona Bipolar Disorder Program at Hospital Clinic - Spain. Experienced psychiatrists carried the diagnosis of Bipolar I or II Disorder confirmed by Structured Clinical Interview for DSM-IV (SCID). All patients with BD were receiving psychiatric medication. Inclusion criteria

for outpatients were: age between 18 and 65 years, and euthymia for at least one month before assessment confirmed by Hamilton Depression Rating Scale (HAM-D-17) and Young Mania Rating Scale (YMRS)  $\leq 7$ . Exclusion criteria for outpatients were a diagnosis of intellectual disability, significant neurologic or physical disease, electroconvulsive therapy (ECT) within the past year and substance abuse or dependence. Criteria for unaffected individuals comprised age between 18 and 65 years, not in use of any psychiatric medication, having no current, past history or first-degree family history of a severe mental disorder, dementia or intellectual disability. All participants provided written informed consent. The local ethical committees from both Brazil and Spain approved all procedures.

## *2.2 Assessments*

All patients completed a structural interview with experienced clinicians that included sociodemographic and clinical aspects. After, experienced clinical psychologists administered the neuropsychological battery. Cognitive domains assessed were inhibitory control (Stroop Color and Word Test)(60), processing speed (Trail Making Test A), cognitive flexibility (Trail Making Test B)(59), verbal fluency (Verbal Fluency Test with letters F-A-S)(61), working memory (Letter-Number Sequencing from WAIS-III)(58); short-term verbal memory (Hopkins Verbal Learning Test–Revised [HVLTR] trials 1-3 or California Verbal Learning Test [CVLT] trials 1-5), long-term verbal memory (HVLTR delayed recall trial or CVLT delayed recall trial)(57,77).

## *2.3 Statistical Analysis*

We performed statistical analyses in R (<https://www.Rproject.org/>).

### *2.3.1 Data Transformation*

TMT-A and B were subtracted by 300 (maximum score) to be compatible with the direction of the other cognitive tests. Cognitive variables were transformed to z-score based on the mean and standard deviation of unaffected subjects (78). We truncated extremely low z-scores ( $<-4.0$ ) to  $z = -4.0$ . All cognitive tests were the same for both samples except verbal memory tests. On the Brazilian sample, we carried out the verbal memory assessment with Hopkins Verbal Learning Test–Revised (HVLT-R), while on the Spanish sample, we assessed with California Verbal Learning Test (CVLT). In order to include a memory domain in our analysis, we converted scores of HVLT-R trials 1-3 and delayed recall trial into z-score based on the mean and standard deviation of the Brazilian sample of unaffected individuals. We performed the same procedure with CVLT trials 1-5 and delayed recall trial based on the Spanish sample of unaffected subjects. After, we gathered the z-scores of HVLT-R trials 1-3 and CVLT trials 1-5 as a short-term verbal memory domain and delayed recall of HVLT-R and CVLT as a long-term verbal memory domain.

### *2.3.2 Cognitive Subgroups*

We performed the hypothesis testing in three steps. First, we used Hierarchical Cluster Analysis (HCA) to investigate the presence of cognitive subgroups in the BD sample using Ward's method and squared Euclidean distance(79,80). We inspected visually the dendrogram generated through HCA to identify the number of clusters. We performed a Discriminant Function Analysis (DFA) to confirm the clusters retained and to investigate the predictive power of the classification.

Second, we checked the variables for outliers and normal distribution using Kolmogorov-Smirnov test. All variables in common with both groups were normally distributed. We performed Student's *t* and Chi-square tests when appropriated to compare the groups. We tested for cluster effects on neuropsychological characteristics through multivariate analysis of variance (MANOVA) with post-hoc Tukey's HSD test for multiple comparisons. Statistical significance was  $p < 0.05$  (two-tailed) for all tests. Z-scores less than -1 standard deviation were considered as moderate impairment. Criteria for severe cognitive impairment were established in z-score  $\leq -2$ .

### *2.3.3 Classification and Regression Tree model*

Lastly, we used the Classification and Regression Tree (CART) model to identify the predictors of cognitive clusters in BD patients. CART algorithm is a non-parametric model with high-order interactions which predicts outcomes based on the average value of observations(48,71). This algorithm uses automatic feature selection in each leaf. Then, we inserted categorical and continuous variables as predictors. Outcomes were cognitive subgroups (intact, selective or global) previously defined. Variables included in the CART analysis were: years of education, age, number of hospitalizations, years of disease, age of onset, first-episode types (depressive or manic episode), first episode psychosis (dichotomous variable: yes or not), family history of mood disorders (dichotomous variable: yes or not), and type of bipolar disorder (Type I or II). We selected these variables because they are widely described in the literature as being related to cognitive performance and greater illness severity. We used the default pruning parameter to avoid overfitting (complexity parameter = 0.01). The number of cases was set of 142 for the root node.



### 3. RESULTS

#### 3.1 Cognitive subgroups

The demographic and clinical variables of the sample are presented in Table 1. The groups (BD and unaffected individuals) had similar gender distribution. Individuals with BD were older and had fewer years of education compared to unaffected subjects (Student's t-test: all  $p \leq 0.049$ ).

The Hierarchical Cluster Analysis (HCA), through the visual inspection of the dendrogram, demonstrated the presence of three cognitive clusters (Figure 1), comprised by 38% of patients with intact cognition ( $n=55$ ), 38% with selective impairments ( $n=56$ ), and 21% with global impairments ( $n=31$ ). The Discriminant Function Analysis (DFA) showed the presence of two discriminant functions, which explained 95.5% and 4.05% of the variance, respectively (Wilks'  $\lambda = 0.15$ ,  $\chi^2 = 257.09$ ,  $p < 0.001$ , Wilks'  $\lambda = 0.86$ ,  $\chi^2 = 26.06$ ,  $p < 0.001$ ). The patients were correctly classified into 93% of the cases, evidencing the validity of the three cognitive clusters. Cognitive Flexibility and Verbal Fluency were domains that better classified BD patients into cognitive clusters by means of correlations between discriminating variables and discriminant functions (Function 1:  $r=0.68$  and  $r=0.38$ . Function 2:  $r= -0.34$  and  $r= -0.19$ , respectively). The cognitive subgroups are shown in Figure 2.

The multivariate ANOVA displayed a significant effect of group comparing the cognitive clusters across neuropsychological variables ( $F_{(12, 270)} = 20.954$ ,  $p < 0.001$ ). The post-hoc test revealed that all cognitive groups are different (Table 2). The intact cognition group had better performance than the other two cognitive clusters. The selective group had also better performance compared to the global impairment group, except for inhibitory control. This group exhibited an intermediate performance between the intact cognition and the global impairment groups. The globally impaired

group had worse performance than the other two cognitive groups. The selective group showed moderate impairment ( $-1 \geq z\text{-score} \geq -2$ ) in working memory, short and long-term verbal memory and severe deficit ( $z\text{-score} < -2$ ) in cognitive flexibility. The global group exhibited moderate deficit in working memory, verbal fluency, and short-term verbal memory. The same group displayed severe neurocognitive impairment in processing speed, cognitive flexibility, and long-term verbal memory. The mean z-scores across domains between the three clusters of BD patients are displayed in Figure 3.

### *3.2 Classification and Regression Tree model*

The tree-based CART prediction model is shown in Figure 4. There were seven terminal nodes, which are results of ‘if-then’ conditions. The split criterion is indicated in each decision node. The most important criterion was years of education, which split the root node into two branches ( $\geq 9.5$  years of education and  $< 9.5$  years of education). About 78% of the sample had more years of education. Additionally, the CART showed the following predictors of cognitive clusters: years of disease ( $< 10$  and  $\geq 10$ ), number of hospitalizations (First split:  $\geq 2.5$  and  $< 2.5$ . Second split:  $< 5.5$  and  $\geq 5.5$ ), age ( $< 58$  and  $\geq 58$ ), and age of onset ( $\geq 28$  and  $< 28$ ) respectively. First-episode type, first episode psychosis, family history of mood disorders and type of bipolar disorder were not included in the model.

A portion of subjects with globally impaired cognition showed less years of education ( $< 9.5$ ) and more years of illness duration ( $\geq 10$ ). The frequency of individuals with global impairment was 62% for this terminal node. Another fraction of the global

group (50% for this terminal node) exhibited more years of education ( $\geq 9.5$ ), a lower number of hospitalizations ( $< 2.5$ ) and were older age ( $> 58$ ).

In relation to subjects with selectively impaired cognition, there were two subgroups: 1) individuals with more years of education ( $\geq 9.5$ ), lower number of hospitalizations ( $< 2.5$ ), younger age ( $< 58$ ), and early-age onset ( $< 28$ ) (66% for this terminal node); 2) individuals with more years of education and a higher number of hospitalizations ( $\geq 5.5$ ) (62% for this node).

The intact cluster subdivided into three groups: 1) subjects with less years of education ( $< 9.5$ ) and less years of illness duration ( $< 10$ ) (100% for this terminal node); 2) patients with more years of education ( $\geq 9.5$ ) and a lower number of hospitalizations ( $< 5.5$ ) (63%); 3) subjects with more years of education ( $\geq 9.5$ ), lower number of hospitalizations ( $< 2.5$ ) with age less than 58 years old, and the late-age onset of BD ( $\geq 28$ ) (50%).

#### **4. DISCUSSION**

Our study identified the presence of three cognitive subgroups of euthymic patients with BD. The cognitive clusters were patients with intact cognition (39%), selectively impaired cognition (39%), and globally impaired cognition (22%). The percentage of subjects in each cluster was similar to previous data, indicating that only a small portion of BD patients exhibited a global cognitive impairment (8,66). Some authors reported that moderate cognitive deficit might be considered when standard deviation is 1 score below the mean of an unaffected subject sample (81–83). The global group displayed neurocognitive deficits in all domains except for inhibitory control. The moderately impaired cognitive functions as working memory, verbal fluency, short-term

verbal memory were below -1 standard deviation. The severely impaired cognitive domains (z-score  $\leq -2$ ) were processing speed, cognitive flexibility, and long-term verbal memory.

On the other hand, the majority of patients showed neuropsychological functioning similar to unaffected subjects (intact cluster) or displayed cognitive impairments in some domains (selective cluster). The selective group showed a mild performance between 0 and -1 standard deviation in inhibitory control, processing speed, verbal fluency consistent with previous works (8,45,66,84). However, the selective cluster had a moderate cognitive deficit in working memory, short-term and long-term verbal memory below -1 standard deviation and a severe deficit in cognitive flexibility below -2 standard deviation.

In relation to predictors of cognitive clusters, the most important criterion to predict neuropsychological subgroups was years of education, subdividing the cognitive clusters into subgroups with more years of education (Intact, Selective, and Global) and less years of education (Intact and Global). Only 22% of the sample had less years of education (<9.5 years). As we know, this variable is an important proxy of Cognitive Reserve (CR), e.g., the brain capacity of resisting to damage due to certain lifetime experiences such as the level of education. Thus, the majority of patients in the global group had fewer years of education and more years of disease. In other words, these patients showed lower CR and were more chronically ill. Previous studies indicated that low CR is associated with neuronal loss before the onset of symptoms, cognitive decline and brain atrophy(85,86). In addition, years of education are positively linked to grey matter volume in patients with dementia(86). In BD patients, CR is a predictor of neuropsychological functioning. Patients with low CR have worse cognitive

performance in several domains, suggesting that CR may play a critical function in the course of BD(25) .

However, years of disease were a factor more capable to specifically discriminate the intact and the global group. In a recent research that used cognitive cluster analysis, authors found a significant difference of years of illness between the cluster with good performance and the cluster with severe impairment. Nonetheless, the selectively impaired group was not different from the cluster with severe impairment and from the cluster with good performance in relation to years of illness(45). The present study results are in line with this early finding, which the globally impaired group had more years of disease than group with good performance. Moreover, others reports have shown that illness duration is negatively associated with processing speed, executive function, attention, and cognitive flexibility(87–92).

The number of hospitalizations was another predictor of the cognitive cluster in our study. This predictor differentiated a portion of intact, selective, and global clusters with lower number of hospitalizations ( $<2.5$ ) from intact and selective clusters with higher number of hospitalizations ( $\geq 2.5$ ). We considered this factor as the number of hospitalizations due to mood episodes. Number of hospitalizations is a harder endpoint with minimum recall bias and probably is strongly related with acute mood episodes in BD. Moreover, rates of hospitalizations are a crucial marker of illness severity associated with worse clinical outcomes(93). As showed by our data, a fraction of the intact group had a lower number of severe mood episodes ( $\leq 5.5$ ) than the selective group ( $>5.5$ ). Several findings are consistent with our data linking the number of hospitalizations and cognitive performance. Recent reports indicate patients with multiple episodes and with many hospitalizations exhibit cognitive deficits in several domains, whereas patients with few episodes had better cognitive performance(94–96).

Furthermore, there is evidence that length of hospital stay is negatively correlated with neuropsychological performance at discharge from inpatient care(97).

Years of education ( $\geq 9.5$ ), number of hospitalizations ( $< 2.5$ ) and older age ( $\geq 58$ ) were predictors of a sub-sample among the global group. This sub-sample had medium education level but was older. An early study concluded that older BD patients had poorer cognitive performance, despite having higher education (98). Furthermore, a few number of hospitalizations associated with an old age were predictors of cognitive global impairment in our study. Similarly, a longitudinal study found that number of hospitalizations was a predictor of cognitive deficit in elderly patients with BD(99). Some authors reported that the number of mood episodes might be a factor for dementia due to decreased CR during mood episodes(69,100,101). A growing body of scientific evidence indicates that the age-related cognitive impairment is higher in BD patients than in healthy controls (102,103). Another longitudinal study provided evidence that older BD patients exhibited severe cognitive deficit and rapid cognitive decline when compared to unaffected subjects(104).

In the other branch (age  $< 58$ ), the decision node split into two terminal nodes according to age of disease onset. The selective group had earlier age of onset ( $< 28$ ) than the intact group ( $\geq 28$ ). A recent meta-analysis demonstrated that earlier age of onset was associated with selective cognitive deficit, specifically in verbal memory and processing speed(105).

One of the limitations of our study is its cross-sectional design. In addition, we did not measure IQ and other premorbid variables as childhood trauma, drug use, and prodromal symptoms. Another limitation was the presence of two different instruments (HVLТ and CVLT) to assess verbal memory in each country. In addition, we

investigated each domain with few neuropsychological tests. Nonetheless, the strength of our work was the large sample size, transcultural study and the use of a new method analysis, not previously used in neuropsychology.

In conclusion, individuals with bipolar disorder could be slip into three cognitive profiles: similar performance to healthy controls, selective impairments in some cognitive functions and global impairments across domains. The most important predictor of these cognitive subgroups was years of education, followed by years of disease, number of hospitalizations due to a mood episode, age and age of disease onset, respectively. These results corroborate with recent findings of neuropsychological heterogeneity in bipolar disorder and suggest that an interaction between premorbid and morbid aspects influence the observed distinct courses of the disease. Future research should focus on other premorbid factors and differences in neuroimaging between cognitive clusters.

**Table 1.** Sociodemographic and clinical characteristics of individuals with Bipolar Disorder and unaffected subjects.

	Individuals with Bipolar Disorder	Healthy Controls	Statistics
Gender F/M [%]	64.9/35.2	63/37	$X^2(1) = 0.24, p = .62$
BD type I/II [%]	83.1/16.9		
Age [mean(SD)]	45.30 (12.24)	42 (14.72)	$T(237.63) = 48.74, p < 0.001$
Years of education [mean(SD)]	12.40 (4.40)	14.8 (4.00)	$T(179.24) = 34.99, p < 0.001$
Age of onset [mean(SD)]	26.36 (9.98)	-	-
Years of disease [mean(SD)]	18.70 (11.87)	-	-
Number of mood episodes [mean(SD)]	11.96 (9.43)	-	-
Number of Hospitalizations [mean(SD)]	3.01 (4.32)	-	-
HAM-D [mean(SD)]	3.40 (2.35)	-	-
YMRS [mean(SD)]	1.22 (1.51)	-	-
<b>Current psychiatric medication</b>			
<i>Mood stabilizers [%]</i>	63.0	-	-
<i>Antipsychotics [%]</i>	48.7	-	-
<i>Benzodiazepine [%]</i>	18.5	-	-
<i>Antidepressant [%]</i>	15.9	-	-

SD: Standard deviation; HAM-D: Hamilton Depression Rating Scale; YMRS: Young Mania Rating Scale



**Table 2.** Comparison between neurocognitive clusters of bipolar disorder and unaffected individuals across cognitive domains (Z scores).

	Clusters				<i>F</i>	Interaction
	Intact BD (n=55)	Selective BD (n=56)	Global BD (n=31)	Controls (n=100)		
Working memory	-0.02 (0.97)	-1.14 (0.92)	-1.88 (0.94)	0.03 (0.97)	42.41	Intact v. Selective <sup>a</sup> Intact v. Global <sup>a</sup> Global v. Selective <sup>a</sup>
Inhibitory control	0.19 (0.93)	-0.26 (0.73)	-0.67 (0.66)	0.00 (1.00)	12	Intact v. Selective <sup>b</sup> Intact v. Global <sup>a</sup>
Processing speed	-0.08 (1.01)	-0.84 (1.03)	-2.82 (1.37)	0.03 (0.96)	61.46	Intact v. Selective <sup>a</sup> Intact v. Global <sup>a</sup> Global v. Selective <sup>a</sup>
Cognitive flexibility	0.50 (1.38)	-2.13 (1.31)	-3.85 (0.35)	0.04(0.96)	142.7	Intact v. Selective <sup>c</sup> Intact v. Global <sup>c</sup> Global v. Selective <sup>c</sup>
Verbal Fluency	-0.03 (1.04)	-0.72(1.22)	-1.81 (0.80)	0.02 (0.98)	27.44	Intact v. Selective <sup>a</sup> Intact v. Global <sup>a</sup> Global v. Selective <sup>a</sup>
Short-term verbal memory	0.15 (0.97)	-1.16 (1.09)	-1.99 (0.83)	0.02 (0.99)	51.11	Intact v. Selective <sup>a</sup> Intact v. Global <sup>a</sup> Global v. Selective <sup>a</sup>
Long-term verbal memory	-0.14 (1.00)	-1.20 (0.96)	-2.14 (1.05)	0.00 (1.00)	42.03	Intact v. Selective <sup>a</sup> Intact v. Global <sup>a</sup> Global v. Selective <sup>a</sup>

Multivariate analysis of variance (MANOVA) with post-hoc Tukey's HSD test for multiple comparisons. Data showed as mean (standard deviation) of z-scores.

<sup>a</sup> p<0.001; <sup>b</sup> p<0.01; <sup>c</sup> p<0.05




Figure 1 – Dendrogram of individuals with bipolar disorder produced by Hierarchical Cluster Analysis, illustrating the arrangement of the cognitive clusters. Abbreviations: Intact (cognitively intact cluster), Selective (selectively impaired cluster), Global (globally impaired cluster).




Figure 2 – Agglomeration of individuals with bipolar disorder produced by Discriminant Function Analysis (DFA) based on cognitive performance in three groups. The higher symbols are the centroids for each cluster.




Figure 3 – Mean of neuropsychological performance between three clusters of individuals with bipolar disorder. The X-axis is the domains cognitive and Y-axis is the value of z-score based on mean and standard-deviation of unaffected subjects in cognitive tests. Statistical tests among groups are shown in Table 2.




Figure 4– Classification and Regression Tree (CART) model using predictors of cognitive clusters in bipolar disorder. Each node shows the predicted class (intact cognition, selective cognitive impairment or global cognitive deficits), the predicted probability of each cluster and the percentage of observations in the node.

## REFERENCES

1. ROSS J, BALDESSARINI LT. Suicide risk and treatments for patients with bipolar disorder. *JAMA* [Internet]. 2003 Sep 17;290(11):1517–9. Available from: <http://dx.doi.org/10.1001/jama.290.11.1517>
2. Gore FM, Bloem PJN, Patton GC, Ferguson J, Joseph V, Coffey C, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. *Lancet* (London, England). 2011 Jun;377(9783):2093–102.
3. Nordentoft M, Mortensen PB, Pedersen CB. Absolute Risk of Suicide After First Hospital Contact in Mental Disorder. *Arch Gen Psychiatry*. 2011;68(10):1058–64.
4. Association AP. *MANUAL DIAGNÓSTICO DSM-5*.
5. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, et al. Functional impairment and disability across mood states in bipolar disorder. *Value Heal J Int Soc Pharmacoeconomics Outcomes Res*. 2010 Dec;13(8):984–8.
6. Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. *Bipolar Disord*. 2007;9(1–2):183–96.
7. Kogan JN, Otto MW, Bauer MS, Dennehy EB, Miklowitz DJ, Zhang H-W, et al. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Bipolar Disord*. 2004 Dec;6(6):460–9.
8. Jensen JH, Knorr U, Vinberg M, Kessing L V, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. *J Affect Disord* [Internet]. 2016;205:378–86. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27573491>
9. Bora E. Developmental trajectory of cognitive impairment in bipolar disorder: comparison with schizophrenia. *Eur Neuropsychopharmacol*. 2015 Feb;25(2):158–68.

10. Gama CS, Kunz M, Magalhães PVS, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. *Rev Bras Psiquiatr* [Internet]. 2013;35(1):70–4. Available from: [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S1516-44462013000100013](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462013000100013)
11. Vieta E, Popovic D, Rosa AR, Solé B, Grande I, Frey BN, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. *Eur Psychiatry*. 2013;28(1):21–9.
12. Lee RSC, Hermens DF, Scott J, Redoblado-Hodge MA, Naismith SL, Lagopoulos J, et al. A meta-analysis of neuropsychological functioning in first-episode bipolar disorders. *J Psychiatr Res*. 2014;57(1):1–11.
13. Craddock N, Owen MJ. The Kraepelinian dichotomy - going, going... but still not gone. *Br J Psychiatry*. 2010 Feb;196(2):92–5.
14. Tabares-Seisdedos R, Mata I, Escamez T, Vieta E, Lopez-Ilundain JM, Salazar J, et al. Evidence for association between structural variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish isolate population. *Psychiatr Genet*. 2008 Dec;18(6):313–7.
15. Parboosing R, Bao Y, Shen L, Schaefer CA, Brown AS. Gestational influenza and bipolar disorder in adult offspring. *JAMA psychiatry*. 2013 Jul;70(7):677–85.
16. MacCabe JH, Wicks S, Lofving S, David AS, Berndtsson A, Gustafsson J-E, et al. Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. *JAMA psychiatry*. 2013 Mar;70(3):261–70.
17. Morgan VA, Croft ML, Valuri GM, Zubrick SR, Bower C, McNeil TF, et al. Intellectual disability and other neuropsychiatric outcomes in high-risk children of mothers with schizophrenia, bipolar disorder and unipolar major depression. *Br J Psychiatry*. 2012 Apr;200(4):282–9.
18. Daruy-Filho L, Brietzke E, Lafer B, Grassi-Oliveira R. Childhood maltreatment and clinical outcomes of bipolar disorder. *Acta Psychiatr Scand*. 2011

- Dec;124(6):427–34.
19. Etain B, Aas M, Andreassen OA, Lorentzen S, Dieset I, Gard S, et al. Childhood trauma is associated with severe clinical characteristics of bipolar disorders. *J Clin Psychiatry*. 2013 Oct;74(10):991–8.
  20. Li X-B, Liu J-T, Zhu X-Z, Zhang L, Tang Y-L, Wang C-Y. Childhood trauma associates with clinical features of bipolar disorder in a sample of Chinese patients. *J Affect Disord*. 2014 Oct;168:58–63.
  21. Noto MN, Noto C, Caribe AC, Miranda-Scippa A, Nunes SO, Chaves AC, et al. Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. *Rev Bras Psiquiatr*. 2015;37(4):280–8.
  22. Quide Y, O'Reilly N, Rowland JE, Carr VJ, Elzinga BM, Green MJ. Effects of childhood trauma on working memory in affective and non-affective psychotic disorders. *Brain Imaging Behav*. 2017 Jun;11(3):722–35.
  23. Marshall DF, Passarotti AM, Ryan KA, Kamali M, Saunders EFH, Pester B, et al. Deficient inhibitory control as an outcome of childhood trauma. *Psychiatry Res*. 2016 Jan;235:7–12.
  24. Forcada I, Mur M, Mora E, Vieta E, Bartres-Faz D, Portella MJ. The influence of cognitive reserve on psychosocial and neuropsychological functioning in bipolar disorder. *Eur Neuropsychopharmacol*. 2015 Feb;25(2):214–22.
  25. Anaya C, Torrent C, Caballero FF, Vieta E, Bonnin CDM, Ayuso-Mateos JL. Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life. *Acta Psychiatr Scand*. 2016 May;133(5):386–98.
  26. Valenzuela MJ, Sachdev P. Brain reserve and dementia: a systematic review. *Psychol Med*. 2006 Apr;36(4):441–54.
  27. Martino DJ, Valerio MP, Szmulewicz AG, Strejilevich SA. The effect of premorbid intelligence on neurocognitive and psychosocial functioning in bipolar disorder. *J Affect Disord*. 2017 Mar;210:226–9.
  28. Cardoso T, Bauer IE, Meyer TD, Kapczinski F, Soares JC. Neuroprogression and Cognitive Functioning in Bipolar Disorder: A Systematic Review. *Curr*



- Psychiatry Rep. 2015 Sep;17(9):75.
29. Berk M, Conus P, Kapczinski F, Andreazza AC, Yucel M, Wood SJ, et al. From neuroprogression to neuroprotection: implications for clinical care. *Med J Aust.* 2010 Aug;193(4 Suppl):S36-40.
  30. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. *Neurosci Biobehav Rev.* 2008;32(4):675–92.
  31. da Costa SC, Passos IC, Lowri C, Soares JC, Kapczinski F. Refractory bipolar disorder and neuroprogression. *Prog Neuro-Psychopharmacology Biol Psychiatry* [Internet]. 2016;70:103–10. Available from: <http://dx.doi.org/10.1016/j.pnpbp.2015.09.005>
  32. Kapczinski NS, Mwangi B, Cassidy RM, Librenza-Garcia D, Bermudez MB, Kauer-Sant'anna M, et al. Neuroprogression and illness trajectories in bipolar disorder. *Expert Rev Neurother.* 2017 Mar;17(3):277–85.
  33. Bourne C, Aydemir O, Balanzá-Martínez V, Bora E, Brissos S, Cavanagh JTO, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: An individual patient data meta-analysis. *Acta Psychiatr Scand.* 2013;128(3):149–62.
  34. Gama CS, Kunz M, Magalhães PVS, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. *Rev Bras Psiquiatr.* 2013;35(1):70–4.
  35. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. *Br J Psychiatry.* 2006 Apr;188:313–20.
  36. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. *Am J Psychiatry.* 1999 Aug;156(8):1264–6.
  37. Reinares M, Colom F, Rosa AR, Bonnin CM, Franco C, Sole B, et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. *J*

- Affect Disord. 2010 Jun;123(1–3):81–6.
38. Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. *Bipolar Disord.* 2011 Feb;13(1):87–98.
  39. Obrocea G V, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. *Biol Psychiatry.* 2002 Feb;51(3):253–60.
  40. Goi PD, Bucker J, Vianna-Sulzbach M, Rosa AR, Grande I, Chendo I, et al. Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. *Rev Bras Psiquiatr.* 2015;37(2):121–5.
  41. Kauer-Sant’Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. *Int J Neuropsychopharmacol.* 2009 May;12(4):447–58.
  42. Gigante AD, Young LT, Yatham LN, Andreazza AC, Nery FG, Grinberg LT, et al. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. *Int J Neuropsychopharmacol.* 2011 Sep;14(8):1075–89.
  43. Pinto JV, Passos IC, Gomes F, Reckziegel R, Kapczinski F, Mwangi B, et al. Peripheral biomarker signatures of bipolar disorder and schizophrenia: A machine learning approach. Vol. 188, *Schizophrenia research.* Netherlands; 2017. p. 182–4.
  44. Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Gasto C, et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. *Psychother Psychosom.* 2000;69(1):2–18.
  45. Bora E, Hidiröglu C, Özerdem A, Kaçar ÖF, Sarisoy G, Civil Arslan F, et al. Executive dysfunction and cognitive subgroups in a large sample of euthymic patients with bipolar disorder. *Eur Neuropsychopharmacol.* 2016;

46. Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. *Acta Psychiatr Scand*. 2016 Aug;134(2):91–103.
47. Bora E. Differences in cognitive impairment between schizophrenia and bipolar disorder: Considering the role of heterogeneity. *Psychiatry Clin Neurosci*. 2016 Oct;70(10):424–33.
48. Bash E. *Machine Learning with R*. Vol. 1, Packt. 2015. 1-396 p.
49. Burdick KE, Russo M, Frangou S, Mahon K, Braga RJ, Shanahan M, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. *Psychol Med* [Internet]. 2014;1–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25065409>
50. Roux P, Raust A, Cannavo AS, Aubin V, Aouizerate B, Azorin J-M, et al. Cognitive profiles in euthymic patients with bipolar disorders: results from the FACE-BD cohort. *Bipolar Disord*. 2017 Mar;19(2):146–53.
51. Drew Conway and John Myles White. *Machine Learning for Hackers: Case Studies and Algorithms to Get You Started*. O'Reilly Media, Inc; 2012. 324 p.
52. Shalev-Shwartz S, Ben-David S. *Understanding machine learning: From theory to algorithms*. Cambridge university press; 2014.
53. First MB, Williams JB, Karg RS, Spitzer RL. *Entrevista Clínica Estruturada para os Transtornos do DSM-5: SCID-5-CV Versão Clínica*. Artmed Editora;
54. Vilela JAA, Crippa JAS, Del-Ben CM, Loureiro SR. Reliability and validity of a Portuguese version of the Young Mania Rating Scale. *Braz J Med Biol Res*. 2005 Sep;38(9):1429–39.
55. Carneiro AM, Fernandes F, Moreno RA. Hamilton depression rating scale and montgomery-asberg depression rating scale in depressed and bipolar I patients: psychometric properties in a Brazilian sample. *Health Qual Life Outcomes*. 2015;13:42.
56. Benedict RHB, Schretlen D, Groninger L, Brandt J. *Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest*

- Reliability. *Clin Neuropsychol*. 1998 Feb;12(1):43–55.
57. Baños JH, Martin RC. California Verbal Learning Test-: D. Delis, J. Kramer, E. Kaplan, B. Ober. San Antonio, TX. The Psychological Corporation, 2000. Elsevier; 2002.
  58. Yates DB, Trentini CM, Delphino Tosi S, Kessler Corrêa S, Poggere LC, Valli F. Apresentação da escala de inteligência Wechsler abreviada (WASI). *Avaliação Psicológica*. 2006;5(2).
  59. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. *Arch Clin Neuropsychol*. 2004;19(2):203–14.
  60. Golden CJ, Freshwater SM. Stroop color and word test. 1978;
  61. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. *Arch Clin Neuropsychol*. 1999;14(2):167–77.
  62. Martino DJ, Strejilevich SA, Scapola M, Igoa A, Marengo E, Ais ED, et al. Heterogeneity in cognitive functioning among patients with bipolar disorder. *J Affect Disord*. 2008 Jul;109(1–2):149–56.
  63. Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. *Schizophr Bull*. 2009 Sep;35(5):1022–9.
  64. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. *Acta Psychiatr Scand Suppl*. 2007;116(434):17–26.
  65. Tohen M, Hennen J, Zarate CMJ, Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. *Am J Psychiatry*. 2000 Feb;157(2):220–8.
  66. Burdick KE, Russo M, Frangou S, Mahon K, Braga RJ, Shanahan M, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. *Psychol Med [Internet]*. 2014;44(14):3083–96. Available

from: [http://www.journals.cambridge.org/abstract\\_S0033291714000439](http://www.journals.cambridge.org/abstract_S0033291714000439)

67. Sole B, Jimenez E, Torrent C, Del Mar Bonnin C, Torres I, Reinares M, et al. Cognitive variability in bipolar II disorder: who is cognitively impaired and who is preserved. *Bipolar Disord.* 2016 May;18(3):288–99.
68. Geoffroy PA, Etain B, Scott J, Henry C, Jamain S, Leboyer M, et al. Reconsideration of bipolar disorder as a developmental disorder: importance of the time of onset. *J Physiol Paris.* 2013 Sep;107(4):278–85.
69. Cardoso T, Bauer IE, Meyer TD, Kapczinski F, Soares JC. Neuroprogression and Cognitive Functioning in Bipolar Disorder : A Systematic Review. 2015;
70. Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. *Acta Psychiatr Scand.* 2016;134(2):91–103.
71. Dykxhoorn J, Hatcher S, Roy-Gagnon M-H, Colman I. Early life predictors of adolescent suicidal thoughts and adverse outcomes in two population-based cohort studies. *PLoS One.* 2017;12(8):e0183182.
72. Tyrovolas S, Tountas Y, Polychronopoulos E, Panagiotakos D. A classification and regression tree analysis for the evaluation of the role of nutritional services on cardiovascular disease risk status of older people living in Greek islands and Cyprus. *Int J Food Sci Nutr.* 2012 Aug;63(5):522–9.
73. Takeuchi M, Takeuchi H, Kawakubo H, Booka E, Mayanagi S, Fukuda K, et al. Perioperative Risk Calculator Predicts Long-Term Oncologic Outcome for Patients with Esophageal Carcinoma. *Ann Surg Oncol.* 2017 Dec;
74. Dennison O, Wu Q, Ickes M. Prevalence of human immunodeficiency virus testing and associated risk factors in college students. *J Am Coll Health.* 2014;62(5):309–18.
75. Hayes T, Usami S, Jacobucci R, McArdle JJ. Using Classification and Regression Trees (CART) and random forests to analyze attrition: Results from two simulations. *Psychol Aging.* 2015 Dec;30(4):911–29.
76. Lantz B. *Machine learning with R.* Packt Publishing Ltd; 2013.

77. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability. *Clin Neuropsychol* [Internet]. 1998 Feb 1;12(1):43–55. Available from: <http://www.tandfonline.com/doi/abs/10.1076/clin.12.1.43.1726>
78. Field A. *Discovering statistics using IBM SPSS statistics*. Sage; 2013.
79. Hermens DF, Redoblado Hodge MA, Naismith SL, Kaur M, Scott E, Hickie IB. Neuropsychological clustering highlights cognitive differences in young people presenting with depressive symptoms. *J Int Neuropsychol Soc*. 2011 Mar;17(2):267–76.
80. Hermens DF, Naismith SL, Chitty KM, Lee RSC, Tickell A, Duffy SL, et al. Cluster analysis reveals abnormal hippocampal neurometabolic profiles in young people with mood disorders. *Eur Neuropsychopharmacol*. 2015 Jun;25(6):836–45.
81. Martino DJ, Strejilevich SA, Marengo E, Ibanez A, Scapola M, Igoa A. Toward the identification of neurocognitive subtypes in euthymic patients with bipolar disorder. *J Affect Disord*. 2014;167:118–24.
82. Jensen JH, Støttrup MM, Nayberg E, Knorr U, Ullum H, Purdon SE, et al. Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools. *J Affect Disord* [Internet]. 2015;187:10–9. Available from: <http://dx.doi.org/10.1016/j.jad.2015.07.039>
83. Iverson GL, Brooks BL, Langenecker SA, Young AH. Identifying a cognitive impairment subgroup in adults with mood disorders. *J Affect Disord*. 2011 Aug;132(3):360–7.
84. Russo M, Van Rheenen TE, Shanahan M, Mahon K, Perez-Rodriguez MM, Cuesta-Diaz A, et al. Neurocognitive subtypes in patients with bipolar disorder and their unaffected siblings. *Psychol Med* [Internet]. 2017/06/07. 2017;47(16):2892–905. Available from: <https://www.cambridge.org/core/article/neurocognitive-subtypes-in-patients-with-bipolar-disorder-and-their-unaffected-siblings/840120434790593ACC476A7C633726CE>

85. Barulli D, Stern Y. Efficiency, capacity, compensation, maintenance, plasticity: emerging concepts in cognitive reserve. *Trends Cogn Sci.* 2013 Oct;17(10):502–9.
86. Premi E, Grassi M, van Swieten J, Galimberti D, Graff C, Masellis M, et al. Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. *Brain.* 2017 Jun;140(6):1784–91.
87. Delaloye C, Moy G, de Bilbao F, Weber K, Baudois S, Haller S, et al. Longitudinal analysis of cognitive performances and structural brain changes in late-life bipolar disorder. *Int J Geriatr Psychiatry.* 2011 Dec;26(12):1309–18.
88. Mora E, Portella MJ, Forcada I, Vieta E, Mur M. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study. *Psychol Med.* 2013 Jun;43(6):1187–96.
89. Eric YW, Halari R, Cheng KM, Leung SK, Young AH. Cognitive performance is impaired in euthymic Chinese patients with Bipolar 1 Disorder. *J Affect Disord.* 2013 Oct;151(1):156–63.
90. Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. *Am J Psychiatry.* 2004 Feb;161(2):262–70.
91. Frangou S, Donaldson S, Hadjulis M, Landau S, Goldstein LH. The Maudsley Bipolar Disorder Project: executive dysfunction in bipolar disorder I and its clinical correlates. *Biol Psychiatry.* 2005 Dec;58(11):859–64.
92. Torrent C, Martinez-Aran A, del Mar Bonnin C, Reinares M, Daban C, Sole B, et al. Long-term outcome of cognitive impairment in bipolar disorder. *J Clin Psychiatry.* 2012 Jul;73(7):e899-905.
93. da Costa SC, Passos IC, Lowri C, Soares JC, Kapczinski F. Refractory bipolar disorder and neuroprogression. *Prog Neuropsychopharmacol Biol Psychiatry.* 2016 Oct;70:103–10.

94. Vieta E, Popovic D, Rosa a. R, Solé B, Grande I, Frey BN, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. *Eur Psychiatry* [Internet]. 2013 Jan [cited 2015 Mar 16];28(1):21–9. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0924933811001842>
95. Robinson L, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: A systematic review of cross sectional evidence. *Bipolar Disord*. 2006;8(2):103–16.
96. Czepielewski LS, Massuda R, Goi P, Sulzbach-Vianna M, Reckziegel R, Costanzi M, et al. Verbal episodic memory along the course of schizophrenia and bipolar disorder: a new perspective. *Eur Neuropsychopharmacol*. 2015 Feb;25(2):169–75.
97. Levy B, Stephansky MR, Dobie KC, Monzani BA, Medina AM, Weiss RD. The duration of inpatient admission predicts cognitive functioning at discharge in patients with bipolar disorder. *Compr Psychiatry*. 2009;50(4):322–6.
98. Rise IV, Haro JM, Gjervan B. Clinical features, comorbidity, and cognitive impairment in elderly bipolar patients. *Neuropsychiatr Dis Treat*. 2016;12:1203–13.
99. Schouws SN, Stek ML, Comijs HC, Dols A, Beekman AT. Cognitive decline in elderly bipolar disorder patients: a follow-up study. *Bipolar Disord*. 2012 Nov;14(7):749–55.
100. Stern Y. Cognitive reserve. *Neuropsychologia*. 2009 Aug;47(10):2015–28.
101. Gildengers AG, Chisholm D, Butters MA, Anderson SJ, Begley A, Holm M, et al. Two-year course of cognitive function and instrumental activities of daily living in older adults with bipolar disorder: Evidence for neuroprogression? Vol. 43, *Psychological Medicine*. Butters, M. A.: 3811 O’Hara Street, Pittsburgh, PA, US, 15213, [buffersma@upmc.edu](mailto:buffersma@upmc.edu); Cambridge University Press; 2013. p. 801–11.
102. Dhingra U, Rabins P V. Mania in the elderly: a 5-7 year follow-up. *J Am Geriatr Soc*. 1991 Jun;39(6):581–3.
103. Depp CA, Lindamer LA, Folsom DP, Gilmer T, Hough RL, Garcia P, et al. Differences in clinical features and mental health service use in bipolar disorder



- across the lifespan. *Am J Geriatr Psychiatry*. 2005 Apr;13(4):290–8.
104. Gildengers AG, Mulsant BH, Begley A, Mazumdar S, Hyams A V, Reynolds Iii CF, et al. The longitudinal course of cognition in older adults with bipolar disorder. *Bipolar Disord*. 2009 Nov;11(7):744–52.
  105. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: A meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. *J Affect Disord*. 2009;113(1–2):1–20.

## **7. Aspectos éticos**

O estudo seguiu as condições estabelecidas pela Declaração de Helsinque e foi submetido ao comitê de ética de cada hospital. Todos os pacientes ou os seus responsáveis legais assinaram o termo de consentimento informado conforme aprovado pelo comitê de ética local, estando livres para decidir, a qualquer momento, sobre sua descontinuidade.

## **8. Considerações finais**

A partir dos dados apresentados, o resultados indicam que há três *clusters* cognitivos no TB: indivíduos cognitivamente intacto, seletivamente prejudicado e globalmente prejudicado. A frequência dos pacientes entre os subgrupos replicam achados anteriores (19).

Os preditores de heterogeneidade cognitiva mais importantes foram anos de educação, anos de doença, número de hospitalizações, idade e idade de início. Esses resultados sugerem uma variedade de trajetórias de doença no TB, impactando de diferentes formas ao longo da doença.

## Referências

1. ROSS J, BALDESSARINI LT. Suicide risk and treatments for patients with bipolar disorder. JAMA [Internet]. 2003 Sep 17;290(11):1517–9. Available from: <http://dx.doi.org/10.1001/jama.290.11.1517>
2. Gore FM, Bloem PJN, Patton GC, Ferguson J, Joseph V, Coffey C, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet (London, England). 2011 Jun;377(9783):2093–102.
3. Nordentoft M, Mortensen PB, Pedersen CB. Absolute Risk of Suicide After First Hospital Contact in Mental Disorder. Arch Gen Psychiatry. 2011;68(10):1058–64.
4. Association AP. MANUAL DIAGNÓSTICO DSM-5.
5. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, et al. Functional impairment and disability across mood states in bipolar disorder. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2010 Dec;13(8):984–8.
6. Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. Bipolar Disord. 2007;9(1–2):183–96.
7. Kogan JN, Otto MW, Bauer MS, Dennehy EB, Miklowitz DJ, Zhang H-W, et al. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disord. 2004 Dec;6(6):460–9.
8. Jensen JH, Knorr U, Vinberg M, Kessing L V, Miskowiak KW. Discrete

- neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. *J Affect Disord* [Internet]. 2016;205:378–86. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27573491>
9. Bora E. Developmental trajectory of cognitive impairment in bipolar disorder: comparison with schizophrenia. *Eur Neuropsychopharmacol*. 2015 Feb;25(2):158–68.
  10. Gama CS, Kunz M, Magalhães PVS, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. *Rev Bras Psiquiatr* [Internet]. 2013;35(1):70–4. Available from: [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S1516-44462013000100013](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462013000100013)
  11. Vieta E, Popovic D, Rosa AR, Solé B, Grande I, Frey BN, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. *Eur Psychiatry*. 2013;28(1):21–9.
  12. Lee RSC, Hermens DF, Scott J, Redoblado-Hodge MA, Naismith SL, Lagopoulos J, et al. A meta-analysis of neuropsychological functioning in first-episode bipolar disorders. *J Psychiatr Res*. 2014;57(1):1–11.
  13. Craddock N, Owen MJ. The Kraepelinian dichotomy - going, going... but still not gone. *Br J Psychiatry*. 2010 Feb;196(2):92–5.
  14. Tabares-Seisdedos R, Mata I, Escamez T, Vieta E, Lopez-Ilundain JM, Salazar J, et al. Evidence for association between structural variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish isolate population. *Psychiatr Genet*. 2008 Dec;18(6):313–7.

15. Parboosing R, Bao Y, Shen L, Schaefer CA, Brown AS. Gestational influenza and bipolar disorder in adult offspring. *JAMA psychiatry*. 2013 Jul;70(7):677–85.
16. MacCabe JH, Wicks S, Lofving S, David AS, Berndtsson A, Gustafsson J-E, et al. Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. *JAMA psychiatry*. 2013 Mar;70(3):261–70.
17. Morgan VA, Croft ML, Valuri GM, Zubrick SR, Bower C, McNeil TF, et al. Intellectual disability and other neuropsychiatric outcomes in high-risk children of mothers with schizophrenia, bipolar disorder and unipolar major depression. *Br J Psychiatry*. 2012 Apr;200(4):282–9.
18. Daruy-Filho L, Brietzke E, Lafer B, Grassi-Oliveira R. Childhood maltreatment and clinical outcomes of bipolar disorder. *Acta Psychiatr Scand*. 2011 Dec;124(6):427–34.
19. Etain B, Aas M, Andreassen OA, Lorentzen S, Dieset I, Gard S, et al. Childhood trauma is associated with severe clinical characteristics of bipolar disorders. *J Clin Psychiatry*. 2013 Oct;74(10):991–8.
20. Li X-B, Liu J-T, Zhu X-Z, Zhang L, Tang Y-L, Wang C-Y. Childhood trauma associates with clinical features of bipolar disorder in a sample of Chinese patients. *J Affect Disord*. 2014 Oct;168:58–63.
21. Noto MN, Noto C, Caribe AC, Miranda-Scippa A, Nunes SO, Chaves AC, et al. Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. *Rev Bras Psiquiatr*. 2015;37(4):280–8.

22. Quide Y, O'Reilly N, Rowland JE, Carr VJ, Elzinga BM, Green MJ. Effects of childhood trauma on working memory in affective and non-affective psychotic disorders. *Brain Imaging Behav.* 2017 Jun;11(3):722–35.
23. Marshall DF, Passarotti AM, Ryan KA, Kamali M, Saunders EFH, Pester B, et al. Deficient inhibitory control as an outcome of childhood trauma. *Psychiatry Res.* 2016 Jan;235:7–12.
24. Forcada I, Mur M, Mora E, Vieta E, Bartres-Faz D, Portella MJ. The influence of cognitive reserve on psychosocial and neuropsychological functioning in bipolar disorder. *Eur Neuropsychopharmacol.* 2015 Feb;25(2):214–22.
25. Anaya C, Torrent C, Caballero FF, Vieta E, Bonnin CDM, Ayuso-Mateos JL. Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life. *Acta Psychiatr Scand.* 2016 May;133(5):386–98.
26. Valenzuela MJ, Sachdev P. Brain reserve and dementia: a systematic review. *Psychol Med.* 2006 Apr;36(4):441–54.
27. Martino DJ, Valerio MP, Szmulewicz AG, Strejilevich SA. The effect of premorbid intelligence on neurocognitive and psychosocial functioning in bipolar disorder. *J Affect Disord.* 2017 Mar;210:226–9.
28. Cardoso T, Bauer IE, Meyer TD, Kapczinski F, Soares JC. Neuroprogression and Cognitive Functioning in Bipolar Disorder: A Systematic Review. *Curr Psychiatry Rep.* 2015 Sep;17(9):75.
29. Berk M, Conus P, Kapczinski F, Andreazza AC, Yucel M, Wood SJ, et al. From neuroprogression to neuroprotection: implications for clinical care. *Med J Aust.* 2010 Aug;193(4 Suppl):S36-40.

30. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. *Neurosci Biobehav Rev*. 2008;32(4):675–92.
31. da Costa SC, Passos IC, Lowri C, Soares JC, Kapczinski F. Refractory bipolar disorder and neuroprogression. *Prog Neuro-Psychopharmacology Biol Psychiatry* [Internet]. 2016;70:103–10. Available from: <http://dx.doi.org/10.1016/j.pnpbp.2015.09.005>
32. Kapczinski NS, Mwangi B, Cassidy RM, Librenza-Garcia D, Bermudez MB, Kauer-Sant'anna M, et al. Neuroprogression and illness trajectories in bipolar disorder. *Expert Rev Neurother*. 2017 Mar;17(3):277–85.
33. Bourne C, Aydemir O, Balanzá-Martínez V, Bora E, Brissos S, Cavanagh JTO, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: An individual patient data meta-analysis. *Acta Psychiatr Scand*. 2013;128(3):149–62.
34. Gama CS, Kunz M, Magalhães PVS, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. *Rev Bras Psiquiatr*. 2013;35(1):70–4.
35. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. *Br J Psychiatry*. 2006 Apr;188:313–20.
36. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. *Am J Psychiatry*. 1999 Aug;156(8):1264–6.

37. Reinares M, Colom F, Rosa AR, Bonnin CM, Franco C, Sole B, et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. *J Affect Disord*. 2010 Jun;123(1–3):81–6.
38. Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. *Bipolar Disord*. 2011 Feb;13(1):87–98.
39. Obrocea G V, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. *Biol Psychiatry*. 2002 Feb;51(3):253–60.
40. Goi PD, Bucker J, Vianna-Sulzbach M, Rosa AR, Grande I, Chendo I, et al. Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. *Rev Bras Psiquiatr*. 2015;37(2):121–5.
41. Kauer-Sant’Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. *Int J Neuropsychopharmacol*. 2009 May;12(4):447–58.
42. Gigante AD, Young LT, Yatham LN, Andreazza AC, Nery FG, Grinberg LT, et al. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. *Int J Neuropsychopharmacol*. 2011 Sep;14(8):1075–89.
43. Pinto JV, Passos IC, Gomes F, Reckziegel R, Kapczinski F, Mwangi B, et al. Peripheral biomarker signatures of bipolar disorder and schizophrenia: A



- machine learning approach. Vol. 188, Schizophrenia research. Netherlands; 2017. p. 182–4.
44. Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Gasto C, et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. *Psychother Psychosom.* 2000;69(1):2–18.
  45. Bora E, Hideoğlu C, Özerdem A, Kaçar ÖF, Sarisoy G, Civil Arslan F, et al. Executive dysfunction and cognitive subgroups in a large sample of euthymic patients with bipolar disorder. *Eur Neuropsychopharmacol.* 2016;
  46. Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. *Acta Psychiatr Scand.* 2016 Aug;134(2):91–103.
  47. Bora E. Differences in cognitive impairment between schizophrenia and bipolar disorder: Considering the role of heterogeneity. *Psychiatry Clin Neurosci.* 2016 Oct;70(10):424–33.
  48. Bash E. *Machine Learning with R.* Vol. 1, Packt. 2015. 1-396 p.
  49. Burdick KE, Russo M, Frangou S, Mahon K, Braga RJ, Shanahan M, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. *Psychol Med [Internet].* 2014;1–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25065409>
  50. Roux P, Raust A, Cannavo AS, Aubin V, Aouizerate B, Azorin J-M, et al. Cognitive profiles in euthymic patients with bipolar disorders: results from the FACE-BD cohort. *Bipolar Disord.* 2017 Mar;19(2):146–53.

51. Drew Conway and John Myles White. Machine Learning for Hackers: Case Studies and Algorithms to Get You Started. O'Reilly Media, Inc; 2012. 324 p.
52. Shalev-Shwartz S, Ben-David S. Understanding machine learning: From theory to algorithms. Cambridge university press; 2014.
53. First MB, Williams JB, Karg RS, Spitzer RL. Entrevista Clínica Estruturada para os Transtornos do DSM-5: SCID-5-CV Versão Clínica. Artmed Editora;
54. Vilela JAA, Crippa JAS, Del-Ben CM, Loureiro SR. Reliability and validity of a Portuguese version of the Young Mania Rating Scale. Braz J Med Biol Res. 2005 Sep;38(9):1429–39.
55. Carneiro AM, Fernandes F, Moreno RA. Hamilton depression rating scale and montgomery-asberg depression rating scale in depressed and bipolar I patients: psychometric properties in a Brazilian sample. Health Qual Life Outcomes. 2015;13:42.
56. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability. Clin Neuropsychol. 1998 Feb;12(1):43–55.
57. Baños JH, Martin RC. California Verbal Learning Test-: D. Delis, J. Kramer, E. Kaplan, B. Ober. San Antonio, TX. The Psychological Corporation, 2000. Elsevier; 2002.
58. Yates DB, Trentini CM, Delphino Tosi S, Kessler Corrêa S, Poggere LC, Valli F. Apresentação da escala de inteligência Wechsler abreviada (WASI). Avaliação Psicológica. 2006;5(2).

59. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. *Arch Clin Neuropsychol*. 2004;19(2):203–14.
60. Golden CJ, Freshwater SM. Stroop color and word test. 1978;
61. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. *Arch Clin Neuropsychol*. 1999;14(2):167–77.
62. Martino DJ, Strejilevich SA, Scapola M, Igoa A, Marengo E, Ais ED, et al. Heterogeneity in cognitive functioning among patients with bipolar disorder. *J Affect Disord*. 2008 Jul;109(1–2):149–56.
63. Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. *Schizophr Bull*. 2009 Sep;35(5):1022–9.
64. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. *Acta Psychiatr Scand Suppl*. 2007;116(434):17–26.
65. Tohen M, Hennen J, Zarate CMJ, Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. *Am J Psychiatry*. 2000 Feb;157(2):220–8.
66. Burdick KE, Russo M, Frangou S, Mahon K, Braga RJ, Shanahan M, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. *Psychol Med [Internet]*. 2014;44(14):3083–96. Available from: [http://www.journals.cambridge.org/abstract\\_S0033291714000439](http://www.journals.cambridge.org/abstract_S0033291714000439)

67. Sole B, Jimenez E, Torrent C, Del Mar Bonnin C, Torres I, Reinares M, et al. Cognitive variability in bipolar II disorder: who is cognitively impaired and who is preserved. *Bipolar Disord.* 2016 May;18(3):288–99.
68. Geoffroy PA, Etain B, Scott J, Henry C, Jamain S, Leboyer M, et al. Reconsideration of bipolar disorder as a developmental disorder: importance of the time of onset. *J Physiol Paris.* 2013 Sep;107(4):278–85.
69. Cardoso T, Bauer IE, Meyer TD, Kapczinski F, Soares JC. Neuroprogression and Cognitive Functioning in Bipolar Disorder : A Systematic Review. 2015;
70. Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. *Acta Psychiatr Scand.* 2016;134(2):91–103.
71. Dykxhoorn J, Hatcher S, Roy-Gagnon M-H, Colman I. Early life predictors of adolescent suicidal thoughts and adverse outcomes in two population-based cohort studies. *PLoS One.* 2017;12(8):e0183182.
72. Tyrovolas S, Tountas Y, Polychronopoulos E, Panagiotakos D. A classification and regression tree analysis for the evaluation of the role of nutritional services on cardiovascular disease risk status of older people living in Greek islands and Cyprus. *Int J Food Sci Nutr.* 2012 Aug;63(5):522–9.
73. Takeuchi M, Takeuchi H, Kawakubo H, Booka E, Mayanagi S, Fukuda K, et al. Perioperative Risk Calculator Predicts Long-Term Oncologic Outcome for Patients with Esophageal Carcinoma. *Ann Surg Oncol.* 2017 Dec;
74. Dennison O, Wu Q, Ickes M. Prevalence of human immunodeficiency virus testing and associated risk factors in college students. *J Am Coll Health.* 2014;62(5):309–18.

75. Hayes T, Usami S, Jacobucci R, McArdle JJ. Using Classification and Regression Trees (CART) and random forests to analyze attrition: Results from two simulations. *Psychol Aging*. 2015 Dec;30(4):911–29.
76. Lantz B. *Machine learning with R*. Packt Publishing Ltd; 2013.
77. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability. *Clin Neuropsychol* [Internet]. 1998 Feb 1;12(1):43–55. Available from: <http://www.tandfonline.com/doi/abs/10.1076/clin.12.1.43.1726>
78. Field A. *Discovering statistics using IBM SPSS statistics*. Sage; 2013.
79. Hermens DF, Redoblado Hodge MA, Naismith SL, Kaur M, Scott E, Hickie IB. Neuropsychological clustering highlights cognitive differences in young people presenting with depressive symptoms. *J Int Neuropsychol Soc*. 2011 Mar;17(2):267–76.
80. Hermens DF, Naismith SL, Chitty KM, Lee RSC, Tickell A, Duffy SL, et al. Cluster analysis reveals abnormal hippocampal neurometabolic profiles in young people with mood disorders. *Eur Neuropsychopharmacol*. 2015 Jun;25(6):836–45.
81. Martino DJ, Strejilevich SA, Marengo E, Ibanez A, Scapola M, Igoa A. Toward the identification of neurocognitive subtypes in euthymic patients with bipolar disorder. *J Affect Disord*. 2014;167:118–24.
82. Jensen JH, Støttrup MM, Nayberg E, Knorr U, Ullum H, Purdon SE, et al. Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools. *J Affect Disord* [Internet].

- 2015;187:10–9. Available from: <http://dx.doi.org/10.1016/j.jad.2015.07.039>
83. Iverson GL, Brooks BL, Langenecker SA, Young AH. Identifying a cognitive impairment subgroup in adults with mood disorders. *J Affect Disord*. 2011 Aug;132(3):360–7.
  84. Russo M, Van Rheenen TE, Shanahan M, Mahon K, Perez-Rodriguez MM, Cuesta-Diaz A, et al. Neurocognitive subtypes in patients with bipolar disorder and their unaffected siblings. *Psychol Med* [Internet]. 2017/06/07. 2017;47(16):2892–905. Available from: <https://www.cambridge.org/core/article/neurocognitive-subtypes-in-patients-with-bipolar-disorder-and-their-unaffected-siblings/840120434790593ACC476A7C633726CE>
  85. Barulli D, Stern Y. Efficiency, capacity, compensation, maintenance, plasticity: emerging concepts in cognitive reserve. *Trends Cogn Sci*. 2013 Oct;17(10):502–9.
  86. Premi E, Grassi M, van Swieten J, Galimberti D, Graff C, Masellis M, et al. Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. *Brain*. 2017 Jun;140(6):1784–91.
  87. Delaloye C, Moy G, de Bilbao F, Weber K, Baudois S, Haller S, et al. Longitudinal analysis of cognitive performances and structural brain changes in late-life bipolar disorder. *Int J Geriatr Psychiatry*. 2011 Dec;26(12):1309–18.
  88. Mora E, Portella MJ, Forcada I, Vieta E, Mur M. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-

- treated, euthymic bipolar patients: a 6-year follow-up study. *Psychol Med.* 2013 Jun;43(6):1187–96.
89. Eric YW, Halari R, Cheng KM, Leung SK, Young AH. Cognitive performance is impaired in euthymic Chinese patients with Bipolar 1 Disorder. *J Affect Disord.* 2013 Oct;151(1):156–63.
90. Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. *Am J Psychiatry.* 2004 Feb;161(2):262–70.
91. Frangou S, Donaldson S, Hadjulis M, Landau S, Goldstein LH. The Maudsley Bipolar Disorder Project: executive dysfunction in bipolar disorder I and its clinical correlates. *Biol Psychiatry.* 2005 Dec;58(11):859–64.
92. Torrent C, Martinez-Aran A, del Mar Bonnin C, Reinares M, Daban C, Sole B, et al. Long-term outcome of cognitive impairment in bipolar disorder. *J Clin Psychiatry.* 2012 Jul;73(7):e899-905.
93. da Costa SC, Passos IC, Lowri C, Soares JC, Kapczinski F. Refractory bipolar disorder and neuroprogression. *Prog Neuropsychopharmacol Biol Psychiatry.* 2016 Oct;70:103–10.
94. Vieta E, Popovic D, Rosa a. R, Solé B, Grande I, Frey BN, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. *Eur Psychiatry [Internet].* 2013 Jan [cited 2015 Mar 16];28(1):21–9. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0924933811001842>
95. Robinson L, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: A systematic review of cross sectional evidence. *Bipolar Disord.* 2006;8(2):103–16.

96. Czepielewski LS, Massuda R, Goi P, Sulzbach-Vianna M, Reckziegel R, Costanzi M, et al. Verbal episodic memory along the course of schizophrenia and bipolar disorder: a new perspective. *Eur Neuropsychopharmacol*. 2015 Feb;25(2):169–75.
97. Levy B, Stephansky MR, Dobie KC, Monzani BA, Medina AM, Weiss RD. The duration of inpatient admission predicts cognitive functioning at discharge in patients with bipolar disorder. *Compr Psychiatry*. 2009;50(4):322–6.
98. Rise IV, Haro JM, Gjervan B. Clinical features, comorbidity, and cognitive impairment in elderly bipolar patients. *Neuropsychiatr Dis Treat*. 2016;12:1203–13.
99. Schouws SN, Stek ML, Comijs HC, Dols A, Beekman AT. Cognitive decline in elderly bipolar disorder patients: a follow-up study. *Bipolar Disord*. 2012 Nov;14(7):749–55.
100. Stern Y. Cognitive reserve. *Neuropsychologia*. 2009 Aug;47(10):2015–28.
101. Gildengers AG, Chisholm D, Butters MA, Anderson SJ, Begley A, Holm M, et al. Two-year course of cognitive function and instrumental activities of daily living in older adults with bipolar disorder: Evidence for neuroprogression? Vol. 43, *Psychological Medicine*. Butters, M. A.: 3811 O'Hara Street, Pittsburgh, PA, US, 15213, buttersma@upmc.edu: Cambridge University Press; 2013. p. 801–11.
102. Dhingra U, Rabins P V. Mania in the elderly: a 5-7 year follow-up. *J Am Geriatr Soc*. 1991 Jun;39(6):581–3.
103. Depp CA, Lindamer LA, Folsom DP, Gilmer T, Hough RL, Garcia P, et al. Differences in clinical features and mental health service use in bipolar disorder



- across the lifespan. *Am J Geriatr Psychiatry*. 2005 Apr;13(4):290–8.
104. Gildengers AG, Mulsant BH, Begley A, Mazumdar S, Hyams A V, Reynolds Iii CF, et al. The longitudinal course of cognition in older adults with bipolar disorder. *Bipolar Disord*. 2009 Nov;11(7):744–52.
  105. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: A meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. *J Affect Disord*. 2009;113(1–2):1–20.